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Interactions between the glycosylated Gag protein of MuLV and murine APOBEC3: 
Novel insight into how MuLVs counteract restriction factors 
 
Chairperson: Leonard Evans, Ph.D. 
 
   APOBEC proteins have evolved in mice and humans as potent innate defences against 
retroviral infections. APOBEC3G (hA3G) in humans and mouse APOBEC3 (mA3) 
deaminate cytidine in single-stranded DNA which ultimately results in hypermutation of 
newly synthesized proviral DNA. Other deaminase-independent mechanisms of 
inhibition have been identified, such as directly inhibiting reverse transcription.  Both 
HIV and murine leukemia viruses (MuLVs) have evolved mechanisms to evade the action 
of the APOBEC proteins.  HIV encodes the Vif protein which binds to hA3G and 
facilitates its rapid degradation through the proteasome. The mechanism(s) by which 
exogenous MuLVs evade mA3 inhibitory activity is unknown.  
 
   Exogenous MuLVs encode a glycosylated gag protein (gGag) originating from an 
alternate CUG start site upstream of the AUG start site of the Gag structural polyproteins.  
gGag is synthesized to similar amounts as the structural Gag polyprotein in MuLV 
infected cells but is glycosylated in the endoplasmic reticulum and undergoes distinct 
proteolytic processing.  The function(s) of gGag remain unclear, but eliminating its 
synthesis through mutation markedly impedes in vivo replication of the virus with very 
little affect on in vitro replication. Endogenous retroviruses have not been found to 
express gGag and are tightly controlled by mA3. APOBEC3 proteins are expressed in 
many tissues in the mouse but are not expressed in most in vitro cell lines. These 
observations are consistent with a link between gGag expression and the evasion of mA3 
by MuLVs.   
 
  Studies described herein demonstrate that gGag is protective against both cellular and 
virion-associated mA3 in vitro and is protective against mA3 in vivo. While there was no 
direct interaction between mA3 and gGag in an infected cell, gGag and mA3 are 
localized in the same compartment in the virion and are able to be coprecipitated together 
from lysed virions. G-to-A hypermutation is not a mechanism used by mA3 to inhibit 
gGag-negative MuLV replication.  Through an affect on reverse transcription, cellular 
and virion-associated mA3 reduce viral transcripts in MuLV infected cells in a gGag-
dependent manner. 
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Chapter 1- Introduction 
1.1 Retroviruses 
 Retroviruses are RNA viruses that replicate through DNA intermediates and 
ultimately are incorporated into the genome of the target cell.  If this occurs in a germline 
cell the retrovirus becomes a permanent component of the host genome that is passed 
down to subsequent generations
177
. Over the course of evolution, the human genome has 
been infected approximately 40,000 times such that about 10% of the genome consists of 
retroviral sequences
177
. The majority of these sequences are no longer full length and do 
not encode a functional retrovirus.  However, several endogenous retroviral elements 
function in important physiological roles such as transcriptional regulation of host 
genes
11,41,46,106
 and the induction of placenta-trophoblast fusion during 
embryogenesis
45,61,160
.   
 Retroviruses are positive sense (+) single stranded (ss) RNA viruses that replicate 
through DNA intermediates generated by the viral polymerase which is termed reverse 
transcriptase
177
.  The viral RNA is comprised of two identical RNA genomes that are 
incorporated into the virion and resemble a large polycistronic messenger RNA
98
. 
Reverse transcription of the viral RNA results in the generation of DNA transcripts which 
are ultimately integrated into the target cell genome as a provirus
177
. Once integrated, the 
provirus can use the cell's transcriptional machinery to transcribe its genome into 
messenger RNA
177
. From this RNA, the retroviral proteins are translated. The translated 
proteins are assembled to create new retroviruses that are subsequently released from the 
cell through budding, allowing for an infection of a new cell. 
1.2 Murine Leukemia viruses 
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 Murine leukemia viruses (MuLVs) are classified in the Baltimore classification of 
viruses as Type IV (+) ssRNA, DNA intermediate retroviruses that are part of the 
Retroviridae family and the gammaretroviral genus
98
. MuLV virions are also classified as 
type C
10
, with a centrally located spherical inner core composed of the nucleocapsid (NC) 
and capsid (CA) proteins
10,98
. The genetic structure of a typical MuLV RNA genome and 
the location within a virion of the gene products it encodes is schematically depicted 
below (Figure 1.1).   Within the core are: the RNA genome, reverse transcriptase (RT), 
integrase (IN), protease (PR), and the tRNA
Pro
 primer
98
. The inner core is surrounded by 
an outer envelope composed of a lipid bilayer that contains the transmembrane (TM) and 
surface (SU) subunits of the envelope (Env) glycoprotein
98
. In contrast to other types of 
retroviruses, type C particles appear to be  assembled largely at the plasma membrane 
during budding
10
. The approximate diameter of a mature MuLV particle is 120nm
10
. 
MuLVs can be either endogenous (integrated into the host genome) or exogenous (passed 
from one host to another)
98
. Further classification of MuLVs has been based on host 
specificity or tropism. Ecotropic
115
 MuLVs infect only mice, and utilize the mCAT-1 
receptor. Amphotropic
81
 MuLVs infect mice and cells of many other species using the 
Pit-2 receptor. Xenotropic
115
 MuLVs, although endogenous to mice, can infect cells of 
many species but do not infect mouse cells, and utilize the Xpr-1 receptor. Polytropic
82
 
viruses can infect many species including mice and humans and also use Xpr-1 as a 
receptor.  Interestingly, the Xpr-1 receptor in most mouse strains is functional for 
polytropic viruses but not for xenotropic MuLVs
102
.  All of the receptors thus far 
identified are multiple membrane spanning proteins
102
. 
 Murine leukemia viruses (MuLVs) were originally identified and named for their 
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ability to cause leukemias in mice
1,47,62,70,75,97,156
.    The term has since been adopted to 
represent a large group of mouse gammaretroviruses. Some MuLVs that cause 
proliferative diseases in mice are named after their discoverers: Gross MuLV by Dr. 
Ludwig Gross (1951)
75
 (lymphocytic leukemia); Graffi MuLV by Dr. Arnold Graffi 
(1955)
70
 (erythroleukemia);  Friend MuLV (F-MuLV) by Dr. Charlotte Friend (1957)
62
 
(erythroleukemia); Moloney (M-MuLV) by Dr. John B. Moloney (1960)
47
 (lymphocytic 
leukemia); Rauscher MuLV (R-MuLV) by Dr. Frank J. Rauscher (1962)
156
 
(erythroleukemia); Kirsten MuLV (Ki-MuLV)  by Dr. Warner H. Kirsten (1967)
97
 
(lymphocytic leukemia); and  Abelson MuLV (A-MuLV) by Dr. Herbert T. Abelson 
(1970)
1
 (B-cell leukemia).  
Figure 1.1. Structure of a MuLV virion. The most inner part of a virion is known as 
the core, which contains the RNA genome, NC, IN and PR surrounded by the CA. The 
CA is surrounded by the MA protein, which helps anchor the lipid membrane of the 
virus which contains the envelope proteins TM and SU. Figure credit: Dr. Leonard 
Evans. 
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1.3 The RNA genome  
MuLV virions include a dimeric RNA genome
125,198
 which is contained within an inner 
core
98,135
. The structure and organization the MuLV genome is depicted (Figure 1.2). The 
viral RNA resembles a large mRNA (~8.3 kb) containing a 5' cap
158
 and is 
polyadenylated at the 3' end
73
.  The RNA genome begins with a 5‟ short terminal repeat, 
R
84,167
, followed by a short region which is termed U5
83
.  Immediately downstream of the  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 1.2. MuLV genomic structure and organization. The proviral DNA is flanked by 
two LTRs, both of which contain a U3, R and U5 region. Following the 5' LTR are signals 
that function in primer binding (PBS), splicing (SD), dimerization of the RNA genome 
(DLS), and packaging (psi). Next are the genes that code for internal structural components 
(Gag), replication (Pol) and receptor recognition (Env). These are followed by a sequence 
required for DNA synthesis (PPT) and an LTR which contains transcriptional regulatory 
sequences. Transcription of proviral DNA into RNA ( ) leads to two major species, the 
full-length genome, and the spliced mRNA that encodes the envelope polyprotein. 
Translation of the full-length RNA yields the polyproteins ( ) gGag, Gag and Gag-Pol.  
Translation of the spliced mRNA yields the Env polyprotein.   These polyproteins are further 
processed by the viral protease ( ) to yield their mature forms (see text). 
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U5 is the primer binding site (PBS), which is complementary to the cellular tRNA
Pro
 
80
 
and is the start site for reverse transcription
80
. The splice donor (SD)
170
 site is after the 
PBS but before the packaging signal (psi)
119
 and thereby avoids virion incorporation of 
spliced env gene mRNA. The psi region provides the packaging signal for the virion 
RNA and also contains the dimer linkage site (DLS) that is required for RNA 
dimerization
131,161
. The next portion of the genome consists of the gag gene
6
 so named 
because the major gene product was initially identified as a group specific antigen.  This 
gene, which partially overlaps with psi, encodes a polyprotein that is proteolytically 
cleaved to yield the structural proteins: matrix (MA, hydrophobic p15
gag
)
7
, 
phosphorylated protein (acidic pp12)
143
, capsid (CA, p30)
142
, and nucleocapsid (NC, 
basic p10)
60
. Upstream of the  gag methionine start site is an alternative leucine start site  
that encodes another polyprotein, termed glycosylated gag (gGag, gp80
gag
)
54
.  gGag  is 
translated in the same reading frame as gag but contains an additional eighty-eight amino 
acids on its N-terminus and appears to undergo distinct post-translational processing 
compared to the Gag polyprotein
54
. The gag gene is followed by the pol gene
6
 which 
encodes the viral protease (PR, p14)
146
 reverse transcriptase (RT, p80)
5
, and integrase 
(IN, p46)
72
. After the pol gene is the splice acceptor (SA) which, with the SD, generates 
the spliced env gene mRNA. The env gene  encodes the surface glycoprotein (SU, 
gp80
env
)
93
, and transmembrane protein (TM, p15
env
)
87
. Following the env gene is the 
polypurine tract (PPT)
178
 which is the initiation site for positive strand DNA synthesis. 
After the PPT is the 3' (U3)
31
 region which contains the transcriptional regulatory 
elements of the virus.  The U3 is followed by the 3‟ short terminal repeat (R)
84,167
. The 
U3 region and U5 region are so named because they are unique 3‟ and 5‟ sequences that 
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Figure 1.3. Replication cycle of MuLV. (1) Binding of viral envelope to cell 
surface receptor. (2) Fusion and entry into the cell. (3) Uncoating of virion (4) 
Reverse transcription yielding proviral DNA. (5) Preintegration complex enters 
nucleus, integrates proviral DNA into host genome. (6) Transcription of provirus. (7) 
Translation of virion components. (8) Assembly at the cell membrane. (9) Budding 
of the virion. (10) Maturation and release of the virion. Figure credit: Jennifer 
Kolokithas. 
are incorporated along with the R region into the long terminal repeat (LTR) found in 
proviral DNA.   
1.4 Replication Cycle 
1.4.1 Binding and entry 
The outer subunit (SU, gp70) of the MuLV envelope protein is responsible for 
recognition of cellular receptors
85
 and the initiation of infection.  The viruses are 
classified into four groups originally based on the infectious host range of the MuLVs and 
later shown to correspond to the utilization of distinct cell-surface receptors
81,82,114
.  After 
SU/receptor binding, the virus enters the cell through a pH-dependent endocytic  
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pathway
92
 and fuses with the membrane, a process that is dependent on the insertion of a 
fusion peptide from the transmembrane (TM, p15
Env
) portion of the viral envelope into 
the cellular membrane
86
. Upon fusion, the virus uncoats (viral core components separate 
from outer membrane of the virion) and reverse transcription of the RNA genome 
proceeds in the cytoplasm
98,135
.  
1.4.2 Reverse transcription 
The RNA genome serves as the template for the synthesis of the DNA provirus mediated 
by the viral RNA-dependent DNA polymerase (RT). As illustrated in Figure 1.2, the RNA 
genome which contains a 5' cap and is polyadenylated at the 3' end, consists of the R, U5 
and PBS at the 5' end of the molecule, followed by the gag, pol and env genes, with the 
PPT, U3 and R on the 3' end. The steps of reverse transcription are depicted 
(Intermolecular model, Figure 1.4). First, the tRNA
pro
 binds to the PBS of the genome
84
. 
From the PBS, using the tRNA
Pro
 as a primer, RT transcribes minus (-) strand DNA in the 
3' to 5' direction ending at the R region
5,84
. The RNase H activity degrades the RNA 
portion of the RNA/DNA hybrid
71
. The newly synthesized DNA (called the minus strand 
strong stop DNA) coupled to the  tRNA primer dissociates from the 5' end of the RNA 
genome and hybridizes to the complementary 3' R region of the genome
32,33
.  Minus 
strand DNA synthesis continues to the PBS at the 5' end of the molecule while the RNase 
H activity of RT degrades the RNA genome, except for the PPT region
44,178
. RT uses the 
PPT RNA as a primer to synthesize (in the 5' to 3' direction) the plus (+) strand of DNA 
to the PBS carried by the strong stop (-) DNA, using the minus strand as a  
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Figure 1.4. Reverse transcription of the viral genome. 1). The tRNA
Pro
 binds to the 
PBS of the RNA genome ( ) and RT transcribes minus (-) strand DNA ( ) in 
the 3' to 5' direction ending at the R region. 2). RT's RNase H activity ( ) 
degrades the RNA portion of the RNA/DNA hybrid. 3). The newly synthesized DNA 
and tRNA primer dissociates from the 5' end of the RNA genome and hybridizes to the 3' 
R region of the genome.  Minus strand DNA synthesis continues to the PBS at the 5' end 
of the molecule while the 4). RNase H activity of RT degrades the RNA genome, except 
for the PPT region. 5). RT uses the PPT RNA as a primer to 6). synthesize (in the 5' to 3' 
direction) the plus (+) strand of DNA to the PBS contained within the strong stop (-) 
DNA, using the minus strand as a template. The resultant strand is called strong stop 
plus (+) strand DNA. 7). The tRNA
Pro
 primer, PPT RNA and all remaining RNA is 
removed. 8). The PBS of the (+) strand can anneal to the PBS of the minus strand and 
RT can further synthesize DNA 9). resulting in a double stranded proviral DNA genome.  
 
9 
 
Figure 1.5. Integration of proviral DNA. 1). The proviral cDNA becomes part of the pre-
integration complex (PIC). 2). The 3' ends of the DNA are nicked by IN to produce 3' 
hydroxyl ends. 3). The PIC is then shuttled into the nucleus, which in the case of MuLVs 
only occurs in actively dividing cells during dissolution of the nuclear membrane. 4). The IN 
produces a 4-6 bp staggered cut in the host genome which acts as a target for the proviral 
genomes free hydroxyl groups to integrate into. 5). The gaps left behind and the non-
complementary ends of the proviral genome are 6). repaired and removed, respectively. 
IN IN
-OH
-OH
-OH
-OH
-OH
-OH
-PO4-
-PO4-
1
2
3
4
5
6
template
178
. The resultant strand is called strong stop plus (+) strand DNA. The tRNA
Pro
 
primer, PPT RNA and all remaining RNA is removed, leaving complementary PBS single 
stranded DNA at the ends of the newly formed DNA genome 
104,195
. The PBS of the (+) 
strand anneals to the PBS of the minus strand and serves as a primer for RT to further 
synthesize DNA producing the proviral DNA genome flanked by two long terminal 
repeats (LTRs) consisting of the U3, R, and U5 regions
104,195
. 
1.4.3 Integration 
The proviral cDNA is incorporated in a nucleoprotein complex termed the pre-integration 
complex (PIC).  The PIC contains the viral proteins IN, CA and pp12
15,72
. The function of 
the CA and pp12 are unclear, however the IN plays a direct role in integration.  The  
 
 
 
 
 
 
 
 
 
 
 
CA
CA
GT
GT
 
10 
 
process of integration is depicted (Figure 1.5). At the ends of the MuLV proviral DNA are 
conserved sequences: 5'-AATG and CATT-3'
16,66
. The 3' ends of the CA are nicked by IN 
to produce 3' hydroxyl ends
16,66
. The PIC is then shuttled into the nucleus where the IN 
produces a 6 bp staggered cut in the host genome generating free phosphates which act as 
nucleophilic targets for the proviral genome‟s free hydroxyl groups
16,66
. The remaining 
gaps in the host genome are repaired and the overhanging sequences of the proviral DNA 
produced by the IN are removed
16,66
. 
1.4.4 Transcription of the provirus 
The proviral sequence from the host genome is transcribed as a cellular gene by RNA 
polymerase II and mediated by transcriptional control elements contained within the 
proviral LTR
42,76
. The 5' LTR (specifically U3)
39,40
 encodes promoter sequences (TATA 
box) that are recognized by cellular transcription factors leading to the synthesis of the 
RNA viral genome
76
, which is 5' capped and 3' polyadenylated. The start of transcription 
is the first nucleotide of the 5‟ R and the polyadenylation signal is near the end of the 3‟ 
R
76
. Some of the full-length RNA genome is spliced to produce env mRNA
57
. Both the 
spliced and unspliced mRNAs serve as templates for translation of viral proteins. 
Unspliced RNA is also transported to the plasma membrane where it is incorporated into 
budding virions.  
1.4.5 Translation and maturation 
 The full-length unspliced mRNA is translated to the gGag, Gag as well as the 
Gag-Pol polyproteins while the spliced mRNA is translated to the Env polyproteins
57
. 
The Gag polyprotein is targeted to the inner cell membrane by myristoylation of the 
amino terminus of the polyprotein.  The Env polyprotein is targeted to the cell 
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endoplasmic reticulum and ultimately to the cellular membrane through glycosylation.  
The polyproteins are further processed during virion assembly by the viral protease, 
which exists as a zymogen on the Gag-Pol precursor
21
. The protease is activated by 
dimerization of the Gag-Pol precursor and the cleavage of the protease from the Gag-Pol 
precursors occurs in trans.  The Gag polyprotein (NH2-p15-pp12-p30-p10-COOH)
8
  is 
cleaved to produce the 4 major components of the internal structure of the virion.  p15 (or 
MA) has a neutral charge and is the most hydrophobic protein of the virus
7
. It is located 
between the lipid bilayer and the core of the virion and retains the myristoyl group 
acquired before cleavage of the Gag polyprotein.  In the context of the polyprotein MA 
functions to align Gag  at the plasma membrane during maturation
157
. The only 
phosphorylated protein in the virion is the acidic pp12. It is thought to be localized to the 
core, binds with low affinity to the RNA genome and may serve some regulatory role
143
. 
The icosahedral shell of the viral core is composed of the neutral p30 (or CA)
142
 which is 
the major structural protein of the virus. Bound to the genomic RNA is the basic p10 (or 
NC), which is a major component of the ribonuclear protein complex
60
. It has very high 
affinity to the packaging signal and the DLS of the RNA genome
60
. The Pol polyprotein 
is generated by cleavage of the Gag-Pol polyprotein and consists of NH2-p14-p80-p46-
COOH. The protease (p14, PR) is responsible for cleavage of the polyproteins into their 
final, mature forms during budding from the cell
146
. Reverse transcriptase (RT, p80) is 
packaged into the core of the virion and is responsible for reverse transcription of the 
RNA genome upon infection of a target cell
8
. Integrase (IN, p46) is also incorporated in 
the core of the virion and is responsible for integrating the proviral DNA that results from 
reverse transcription of the viral RNA genome into the host DNA
72
. The Env polyprotein 
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is produced from a spliced viral mRNA and is organized as NH2-gp70-p15
Env
-COOH
6
. 
The glycosylated gp70 is the surface subunit (SU) of the envelope protein and is localized 
on the lipid membrane of the virion
93
. It is responsible for the virus's host-range and 
binding to the cellular receptor
93
. The transmembrane (TM) portion of the envelope is 
responsible for anchoring the SU to the virion by disulfide linkage and also contains a 
fusion peptide that is required for the virus to fuse to the membrane of a target cell
87
. The 
viral RNA is packaged as a dimer along with the tRNA
pro 98
. Immature virions start to bud 
from the cell while the protease is continuing to cleave the Gag polyprotein.
146
. 
1.5 Pathology and the 5 prime leader sequence 
 Many retroviruses have been discovered because of their ability to cause disease 
in animals
1,47,62,70,75,97,156
. Various strains of MuLV were discovered because of their 
pathogenicity in vivo
1,47,62,70,75,97,156
. Many studies of these MuLVs using mutational 
analyses or chimeric viruses have been aimed at determining the viral components 
responsible for pathogenesis and in vivo dissemination. Figure 1.6 lists some of the 
functions of the 5' leader sequence discerned from such studies.  Among these are studies 
of chimeric viruses between F-MuLV and M-MuLV.  F-MuLV induces early hemolytic 
anemia followed by erythroleukemia
176
 and M-MuLV causes lymphocytic leukemia
116
. 
Molecular clones between M- and F-MuLV in which the LTRs of F-MuLV and M-MuLV 
were exchanged resulted in an alteration in pathology.  M-MuLV carrying the LTR of F-
MuLV induced erythroleukemia while F-MuLV carrying the LTR of M-MuLV induced 
lymphocytic leukemia
24
. Another study revealed that the 5' U5-Gag-Pol region was 
important for viral dissemination and disease in vivo, but not for replication in vitro
174
. 
Later studies specifically mapped attenuation of disease using mutant F-MuLV 
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constructs. A mutation abrogating the expression of gGag attenuated disease in vivo but 
the mutant was still able to replicate similarly to the wild-type virus in cell culture
36
. It 
was also found that 6-7 weeks after infection the majority of the gGag mutants isolated 
had reverted back to expressing gGag, indicating that the gGag mutations were under 
strong selection in vivo
36
. CasBrE-MuLV is another ecotropic MuLV that was isolated 
from mice and has been extensively studied because it causes a severe neurodegenerative 
disease
63-65,127,150-153
. Constructs replacing the 5' leader (U5-Gag) sequence of CasBrE 
with F-MuLV (CasFrE) showed a rapid acceleration of disease
150
. The sequences 
responsible for this acceleration mapped to the N-terminus of gGag (construct  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. The 5' leader sequence of MuLV. The 5' leader sequence of MuLV has been 
linked to many functions that are essential for retroviral replication and disease induction. 
The boxes (  ) represent the span of the sequence that has been identified to have a 
certain function in the retroviral life cycle. 
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CasFrKP)
153
. A mutant that abrogated the expression of gGag (CasFr-3+4) was unable to 
induce neurodegenerative disease and showed reduced dissemination in vivo
153
. The 
mutant virus also showed revertants after infection, suggesting again a strong selective 
pressure for gGag expression
153
.  It is noteworthy that the revertants did not restore the 
original gGag but rather were second site reversions which introduced new initiation 
codons downstream of the original gGag start site.  Nonetheless, both the replicative and 
pathogenic functions of the mutant viruses were restored.  When mice were inoculated 
with revertants the viruses replicated and induced rapid disease similar to the wild-type 
virus
151
. 
1.5.1 Glycosylated Gag 
 All exogenous MuLVs encode an alternate form of the Gag polyprotein that is 
glycosylated (gGag)
54,112,154
. gGag was first recognized on AKR MuLV-induced tumor 
cells as an antigen
112
.  The glycosylated protein is translated from the same viral mRNA 
as Gag but uses a CUG start codon that is upstream of the AUG start codon for 
Gag
54,65,133
. The coding region of gGag also overlaps with those required for RNA 
packaging, ribosome binding, IRES-dependent translation and pathological determinants. 
The alternative start codon for gGag results in an additional 88 N-terminal amino acids 
on the Gag polyprotein. These additional amino acids contain a signal peptide that targets 
gGag to the rough endoplasmic reticulum for glycosylation where it is then exported to 
the cell membrane
65,147
. The proposed glycosylation sites exist in the p15 and p30 regions 
of the polyprotein. gGag has been reported to be cleaved near the end of the CA region, 
producing two products that migrate between 55kD and 45 kD on an SDS-PAGE gel. 
Some of the C-terminal cleavage product of gGag is secreted while a pool of the N-
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terminal portion adopts a type II integral membrane configuration(Ncyto, Cexo)
65,147
. Some 
gGag is incorporated into the virion, but the specific amount has yet to be determined
63
. 
The levels of Gag and gGag protein expressed in an infected cell are similar
65
. Mutant 
viruses that lack gGag are able to replicate efficiently in vitro, however, in vivo gGag 
mutants are severely limited in their ability to replicate
63,65,121
.  Reversion is strongly 
selected for in vivo suggesting an important replicative role for gGag. The role of the 
gGag protein is unknown in viral replication, though it has been suggested that it is 
required for efficient budding and release in vitro
121
.  
1.6 Restriction Factors 
 All eukaryotes carry mobile genetic elements in their genomes
177
. Retroelements 
are in the family of mobile DNA sequences that use RNA intermediates and reverse 
transcriptase to insert into a new point in the genome. In many species these elements 
make up a large amount of the total amount of genetic content (10% in humans)
177
 and  
represent insertion events into host genomes caused by retroviral infections over the 
course of evolution
177
. In some instances these mobile elements can insert themselves 
into regions of the genome that affect the control of cellular growth
177
 which obviously 
could be detrimental to the survival of the host. Exogenous retroviruses can also infect 
and insert themselves into the genome of their host, in many cases causing proliferative 
diseases
37,38,117,171,194
. Over evolutionary time, many species have evolved mechanisms to 
limit or restrict active retroviral replication
9,69
. In many cases retroviral expression is 
suppressed by methylation of promoter sequences
9,69
, however, there are also distinct 
factors that function to restrict retroviral replication.  These „restriction factors‟ operate 
on many different aspects of the retroviral life cycle ranging from viral receptor blockade 
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to viral RNA degradation
9,69
.   
1.6.1 Fv1 restriction 
 One of the first restriction factors identified was Fv1 (Friend virus susceptibility 
1) in mice
118
. It was found to control susceptibility to F-MuLV disease, but has since been 
shown to affect other MuLVs. There are two different alleles for the Fv1 gene, Fv1
b
 (in 
Balb/c mice) and Fv1
n
 (in NIH/swiss mice).  N-tropic viruses replicate efficiently Fv1
n
 
mice but inefficiently in Fv1
b
 mice.  Conversely, B-tropic viruses replicate efficiently in 
Fv1
b
 mice but not in Fv1
n
 mice.  Crosses between Fv1
n
 and Fv1
b
 mice are resistant to 
infection by N- or B-tropic viruses, while some viruses are NB-tropic and cannot be 
blocked by either Fv1 allele
148
. Viral tropism is determined by one amino acid (residue 
110) in the capsid (CA)
103
. The restriction mechanism of Fv1, which is thought to be 
related to an endogenous retroviral gag protein, is thought to involve prevention of the 
preintegration complex (PIC) from entering the nucleus, however the exact mechanism 
has yet to be fully elucidated
155
. Several human cell lines infected with N-tropic MuLVs 
encapsulated by the vesicular stomatitis virus-G envelope protein are also resistant to 
infection, but do not carry Fv1
b
. Interestingly, the viral tropism in these human cells was 
determined by the same residue in the CA (residue #110) of MuLVs. This resistance was 
initially referred to as Ref1 (Restriction Factor 1; human antiretroviral activity related to 
Fv1)
190,191
 and was observed in cells of many different species. Through cDNA 
expression library screening, the activity of Ref1 was connected to a protein, TRIM5α
184
. 
The mechanism of this restriction is currently under investigation but is thought to be 
similar to that of Fv1.  
1.6.2 Fv4 restriction 
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 After the identification of Fv1, another gene, Fv4, was found to restrict certain 
retroviruses in Japanese wild mice
91,137
. The ecotropic MuLVs (able to infect only mice) 
use the murine cationic amino acid transporter (mCAT) as their cell-surface receptor for 
infection. Mice with mCAT and Fv4, however, are resistant to infection by ecotropic 
MuLVs. Fv4 was found to be a defective envelope (env) gene of a provirus expressed at 
the cell surface
88,89
. The Fv4 gene product is able to bind directly to mCAT, preventing 
ecotropic MuLV infection by  receptor blockade
89
. 
1.6.3 HIV-1, Vif, and the discovery of APOBEC3 
 Human Immunodeficiency virus-1 (HIV-1) has also been shown to be restricted to 
certain cell types. Evidence of this first emerged with the study of an accessary protein of 
HIV-1, virion infectivity factor (Vif). Viruses lacking Vif (HIV-1 ∆Vif) were unable to 
spread in CD4
+
 T cells or macrophages as well as some transformed T-cell lines 
(nonpermissive cells). However, these same viruses were able to spread in other T-cell 
lines (SupT1 and Jurkat) and in permissive, nonhematopoietic cells (COS, HeLa, and 
293T)
180,197
. One important observation made in these experiments was that 
nonpermissive cells were able to produce HIV-1 ∆Vif virions, but progeny viruses from 
these cells were unable to replicate in any target cell line regardless of whether it was 
permissive or nonpermissive.  One possible explanation for this phenomenon was the 
existence of a host factor able to inhibit viral replication in the absence of Vif but 
abrogated when Vif was expressed.  Such a factor was eventually identified by using 
subtractive hybridization techniques with two cell lines: CEM-S (permissive) and CEM-
SS (nonpermissive).  A gene was cloned that could convert permissive into 
nonpermissive cells upon transfection and expression. This clone was CEM15
172
, which 
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was later found to be a member of the apoplipoprotein B mRNA-editing, enzyme-
catalytic, polypeptide-like  family termed human APOBEC3G (hA3G). The expression of 
hA3G correlated with the permissiveness of cell lines.  Furthermore, virions from 
nonpermissive cells infected with Vif-deficient HIV-1 were shown to incorporate hA3G 
accounting for their inability to replicate efficiently in either permissive or non-
permissive target cell lines.   
1.6.4 Human APOBEC3G 
 hA3G is a member of a family of cytidine deaminases that is restricted to certain 
tissues that exhibit both RNA and DNA editing activity
189
. Members of this family 
include activation induced deaminase (AID) and APOBEC1-4, with APOBEC3 having 
several isoforms designated A through H
35
. These enzymes catalyze the deamination of 
the C4 position of the cytidine base. APOBEC1 has  been found to regulate cholesterol 
and lipid metabolism
129
. Another family member, AID, is required for somatic 
hypermutation and class switch recombination in germinal center B cells
130
.  
 A member of the APOBEC3 family, hA3G, has been identified as an inhibitor of 
retroviral replication.  A principal mechanism by which this occurs is through cytidine 
deamination of single stranded (ss) DNA transcripts during reverse transcription. The 
inhibitory activity of hA3G is dependent on two catalytic domains (CDs). CD1 mediates 
RNA
23
 binding and incorporation into the virion and CD2 functions as the deaminase 
active site
134
.  Encapsidation of hA3G requires the nucleocapsid (NC) region of HIV-1 
Gag
186
, and as few as 7 APOBEC molecules incorporated into a HIV-1 ∆Vif virion are 
sufficient to inhibit the virus in the next round of infection
200
. The deamination-dependent 
mechanism for hA3G is depicted (Figure 1.7). In the target cell, virion-associated hA3G 
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Figure 1.7. APOBEC3 and G-to-A hypermutation activity. During assembly at the 
cellular inner membrane, APOBEC3 is incorporated into budding virions. Upon a 
subsequent infection of a target cell, APOBEC3 exerts its deaminase activity during 
reverse transcription. The newly formed transcripts are deaminated. This can lead to 
either integration of the mutated transcripts or recognition of the transcripts by cellular 
enzymes that lead to transcript degradation. Figure credit: Jennifer Kolokithas. 
introduces dC to dU mutations in the minus strand viral DNA formed during reverse 
transcription
185
. These DNA strands may be degraded by apurinic-apyrimidinic 
endonuclease or uracil DNA glycosylase
201
.  Strands that are not degraded and serve as a 
template for plus strand synthesis incorporate A residues rather than G residues at the 
deaminated positions.  Extensive G-to-A mutations render the provirus inactive.   
 
 
 
 
 
 
 
 
 
 
 
 
Furthermore, hA3G appears to inhibit viral replication through deaminase-independent 
mechanisms. One mechanism appears to operate through binding RNA via CD1, 
sterically  blocking the tRNA
Lys3
 primer binding during reverse transcription initiation
77
. 
Another mechanism has been reported to be independent of the catalytic domains and is 
mediated by binding of hA3G to the HIV integrase, further inhibiting the virus‟s ability to 
replicate
124
. The promiscuity of the deaminase activity of hA3G requires it to be 
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sequestered to the cytoplasm
199
. Cellular localization, however, is not the only 
mechanism involved in controlling hA3G‟s activity.  It associates with a high molecular 
mass (HMM) ribonucleoprotein (RNP) complex in resting CD4
+
 T cells in the thymus
29
, 
where hA3G bound to RNA is inactive
29
. In contrast, in circulating CD4
+
 T cells hA3G 
associates with a low molecular mass (LMM) RNP complex where it is active.  Mitogens 
control the switch between HMM and LMM  complexes
183
, though HMM complexes can 
be artificially changed to LMM complexes by treatment with RNase A
29
.  LMM hA3G is 
not recognized by Vif, therefore LMM hA3G can restrict entering viruses whether or not 
they encode Vif. The identification of HMM and LMM complexes was the first evidence 
that hA3G can affect HIV-1 replication without being incorporated into the virion
29
 
though the authors claiming this recently retracted their study. Unlike virion-associated 
hA3G, the antiviral activity of LMM hA3G does not involve DNA editing, but rather 
inhibits the production of reverse transcription product (Figure 1.8). Neither LMM- nor 
HMM-associated hA3G is incorporated into virions. Only newly synthesized hA3G is 
 
 
 
 
 
 
 
 
Figure 1.8. Deaminase-independent activity. APOBEC3 proteins have been found 
also to inhibit retroviral replication through deaminase-independent activity, such as 
blocking reverse transcription or integration. Figure credit: Jennifer Kolokithas. 
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Figure 1.9. APOBEC3 and 
Vif. HIV encodes an 
accessory protein known as 
Vif, which can bind to 
APOBEC3 during retroviral 
assembly and lead to its 
proteasome-dependent 
degradation. This allows the 
HIV virions to prevent 
encapsidation and continue 
to replicate. Figure credit: 
Jennifer Kolokithas. 
incorporated into virions, but is enzymatically inactive
179
 because of interactions with the 
HIV RNA genome and Gag proteins, similar to what is observed in HMM complexes
179
. 
As noted above, the binding of hA3G to the genome impairs the initiation of reverse 
transcription
179
.  Once reverse transcription begins, RNase H degradation of the RNA 
releases hA3G allowing cytidine deamination of the minus-strand DNA substrate 
produced from reverse transcription
179
.  
1.6.5 Murine APOBEC3 and Murine Leukemia viruses 
 HIV-1 encodes a gene product, Vif, which counteracts the antiviral effects of 
hA3G. Vif binds to the N-terminus of hA3G and recruits an ubiquitin ligase complex that 
marks hA3G for destruction in the proteasome
34
 (Figure 1.9). Vif has also been shown to 
impair the translation of hA3G mRNA
128
 and prevent encapsidation by binding to  
 
 
 
 
 
 
 
 
 
hA3G
141
. Similar to HIV and hA3G, MuLVs have evolved a mechanism(s) to evade the 
action of mA3 and are largely insensitive to its actions
13,18,43,100,110,145,162
, however, 
MuLVs do not encode a Vif like accessory protein. While there are 7 family members of 
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A3 in humans, mice contain only one
26
. mA3 exhibits a number of differences from 
hA3G.  The deaminase activity of mA3 resides in the CD1 while the RNA binding and 
encapsulation into the virion resides in CD2
78
. As noted above the converse is true of 
hA3G.  Unlike hA3G, two splice variants (delta-exon 2 and delta-exon 5) have been 
identified for mA3
159,164
. Different mouse strains express different amounts of each 
variant as well as the full length protein
159,164
. Different inhibitory effects of these 
variants on the in vivo replication of certain MuLVs have been reported but remain a 
subject of debate
159,164
. Recent studies have identified mA3 as Rfv3
164
; a gene involved in 
the resistance of certain mouse strains to the induction of acute erythroleukemia in adult 
mice by the Friend virus complex of the F-MuLV and a replication-defective pathogenic 
virus termed the spleen focus-forming virus (SFFV)
164
. The mechanism(s) by which mA3 
affects replication of the Friend virus complex remain unclear and warrant further 
investigation.  Deaminase-dependent and -independent mechanisms have both been 
associated with mA3, though the exact nature of these mechanisms remains 
unclear
26,27,164
.   
 It is unknown how exogenous MuLVs largely resist mA3 activity. It is of note that 
APOBEC3 family members from both humans and mice inhibit endogenous LTR 
retrotransposons/retroviruses. This includes Human Endogenous Retroviruses (HERVs), 
murine intracisternal A-particle (IAP), and MusD sequences
12,49,50
. Interestingly, one 
major difference between endogenous and exogenous (MuLVs) retroviruses in the mouse 
is the absence of an alternate initiation sequence in endogenous retroviruses for gGag. 
1.7 Significance 
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 Mice as well as other mammals contain a very large number of endogenous 
retroviruses comprising about 10% of the genome
177
.  Transcripts of these viruses are 
expressed in a very controlled fashion throughout life and likely are involved in a number 
of physiological processes
49,50
.  Endogenous retrovirus replication may lead to insertional 
mutagenesis as well as inappropriate expression of retroviral proteins, thus it is likely that 
the host has developed mechanisms to control such replication. The evolution of several 
restriction factors that act post-transcriptionally, such as the APOBECs, may reflect this 
necessity.  In contrast to replication competent exogenous MuLVs, all of which encode 
gGag, no endogenous proviruses encode this protein and are controlled in part by mA3
49-
51,90,113
. Mutant viruses that lack gGag are able to replicate efficiently in vitro but are 
severely restricted in vivo
63,65,121
. These observations are consistent with the possibility 
that gGag may serve to evade the action of mA3.  Some reports in the literature suggest a 
direct interaction of mA3 with gag encoded proteins
110,123,162,188
, however, a direct 
interaction between mA3 and gGag has not been investigated.   
Elucidation of the mechanism(s) by which MuLVs evade the action of mA3 may 
provide additional insight into the means by which mammals evade the action of 
retroviruses.  Furthermore, it is has recently been reported that exogenous MuLVs that are 
resistant to mA3, pseudotype endogenous viruses and allow their transfer to cells of other 
species
52,53,55,56
.  This may be of  particularly interest in light of recent reports indicating 
cross-species retroviral infections from mouse to humans
120,166,193
.   
 
 
 
 
24 
 
Chapter 2- Experimental rationale and pilot experiments. 
 The effects of hA3G on HIV replication have been tested by many experimental 
methods, each with unique advantages and disadvantages. Many methods to examine the 
effect of mA3 on MuLV replication have been adopted from studies with 
HIV
2,14,18,30,43,90,100,101,110,149,162,203
.  In addition, other approaches examining the effects of 
mA3 and gGag on MuLV replication have been developed.  This chapter discusses the 
rationale for the methods used in experiments presented throughout this dissertation. 
2.1 Selection and generation of cell types   
 At the onset of these studies nearly all reports dealing with the effects of mA3 on 
MuLV replication examined the effects of transfection of MuLV and mA3 expression 
vectors in the 293T human embryonic kidney stem cell line transformed with the SV40 
large T antigen
2,18,43,110,162,188,203
.  There are a number of potential difficulties with this 
approach.  First, it is unclear if protein processing in this human cell line parallels that 
observed in mouse cells
202
.  Further, because of variation in transfection efficiency, the 
expression of these vectors may vary from cell to cell and from experiment to 
experiment.  In addition, this approach is limited to examining virion-associated mA3 
rather than the effect of cellular mA3 on virus infection.  In this regard, primary bone 
marrow-derived dendritic cells from mA3 knockout (KO) mice are more susceptible to 
infection by MuLVs than their mA3-expressing wild-type (wt) counterparts
123
 .  To 
circumvent some of these difficulties stable mouse cell lines expressing mA3 were 
developed.  The lines chosen were NIH3T3 (3T3) and Mus dunni cells which do not 
constitutively express mA3 as determined by quantitative PCR (qPCR) analyses (data not 
shown).    
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 To generate stable cell lines expressing mA3, a pcDNA3 plasmid encoding the 
full length mA3 derived from the Balb/c mouse strain and tagged at the C-terminus with 
hemagglutinin (HA)
18
 was used to transfect the cell lines which were subsequently 
selected in geneticin (G418).  As no suitable antibody to mA3 was available, experiments 
involving immunoblotting and immunoprecipitation required the use of a tagged version 
of mA3.    
2.2 Selection of MuLVs 
 To study the affects of gGag on viral replication in mA3 expressing cells, the 
CasFrKP and CasFr-3+4 MuLVs were chosen. CasFrKP (gGag
+
) is a MuLV derived from 
the wild mouse ecotropic virus CasBrE and contains a short sequence of the F-MuLV, 
FB29, which includes the initiation site of the gGag protein
152
.  CasFr-3+4 (gGag
-
) is a 
derivative of CasFrKP in which two mutations have been introduced to disrupt the 
initiation site of gGag at the -3 and +4 positions of the Kozak consensus sequence
153
. 
These MuLVs have been studied extensively to determine the role of gGag in 
pathogenesis as well as in in vivo and in vitro replication
30,58,63-65,151,153
.  It has been 
established using gGag-specific peptide antibodies that gGag is expressed in infected 
cells and that an N-terminal cleavage product of gGag is incorporated into the virion
63
. 
2.3 In vitro infectivity assays 
 Most studies that have examined the effects of human APOBEC3G (hA3G) on 
replication have focused on the action of virion-associated hA3G upon infection of naïve 
target cells
17,20,22,23,34,77,96,100,124,126,128,132,179
.  However, the results of one study suggest 
that cellular hA3g can inhibit infection by HIV virions early after entry
29
.  It was of 
interest to study the effects of both cellular mA3 and virion-associated mA3 on MuLV 
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replication and determine if either exerted its effect in a gGag-dependent manner.  In 
order to examine the effects of cellular mA3 on viral replication, gGag
+
 or gGag
-
 viruses 
harvested from cell cultures that did not express mA3 were used to infect both cells that 
express and cells that do not express mA3.  Infectivity was quantified using either a focal 
immunofluorescence assay (FIA) or assays in which a reporter gene was expressed.  To 
analyze the effects of virion-associated mA3 on replication, gGag
+
 or gGag
-
 viruses were 
harvested from cell cultures expressing mA3.  The mA3-containing viruses were 
compared to viruses harvested from cells that did not express mA3 by their infectivity of 
Mus dunni cells.  Infectivity was quantified using either the FIA or reporter assays and 
the data was normalized by RT activity of the virions in the supernatant as well as p30 
quantification in order to deduce the specific infectivities of the viruses.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. In vitro assay system. To test the effect of cellular mA3 on MuLV 
replication, gGag
+
 or gGag- MuLVs were used to infect cells expressing or not 
expressing mA3 (Initial infection). To test the effect of virion-associated mA3 on 
MuLV replication, gGag
+
 or gGag- MuLVs produced from cells expressing or not 
expressing mA3 (Initial infection) were used to infect Mus dunni cells (subsequent 
infection). 
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2.3.1 Focal immunofluorescence assay  
 This assay
175
 exploits the display of virally encoded proteins on the surface of 
infected cells.  Using antibodies specifically reactive to the viral proteins, infected cells 
decorated with the antibody can be detected either by direct conjugation of a fluorescent 
dye to the antibody or, more commonly, by detection using a fluorescently conjugated 
second antibody directed at immunoglobulin (Ig).  Sparsely seeded cells are exposed to 
the virus and allowed to grow to confluence.  An infectious event can be quantified by 
counting focal areas of infected cells that arise either from virus spread or by replication 
of an initially infected cell.     
 
 
 
 
 
 
 
  
  
 
 
  
 
Figure 2.2. Focal immunofluorescence assay. The FIA methodology takes advantage of late 
stages in the viral replication cycle. During assembly of virions at the cell surface, infected 
cells can be detected by labeling viral specific antigens with antibodies. This can be done 
with directly conjugated antibodies specific for viral antigens or with labeled secondary 
antibodies specific to the Ig that was used to bind to the viral antigen. Inset: A focus of 
infected cells. Figure adapted from http://www.nimr.mrc.ac.uk/research/kate-bishop  by Kate 
Bishop, used with permission. 
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 Initial studies using the FIA examined the effects of cellular mA3 on infectivity of 
MuLVs and on cell-free passage of viruses on cell lines.   The effects of cellular mA3 
were performed by comparing virus titers in normal cell lines and in cell lines expressing 
mA3.  Both 3T3 cells and Mus dunni cells were examined and in both cells lines a 
significant reduction in infectivity was observed with the gGag-deficient virus in cells 
expressing mA3 (Figure 2.3).      
   
 
 
 
 
 
 
 
 
2.3.2 Passaging of viruses on mA3 cells 
 In vivo studies of CasFr-3+4 as well as other gGag-negative MuLVs revealed a 
marked selection for second site revertants that expressed gGag
121,151
. Considering that 
the initial experiments suggested that gGag facilitates replication in the presence of mA3, 
it is possible that mA3 is an important component of the in vivo selection for gGag and 
that similar revertants might be generated in the in vitro system.   If revertants were 
generated in vitro, one might expect them to persist in the mA3-expressing lines after 
Figure 2.3. Cellular mA3 and infectivity. A). 3T3 or 3T3/mA3 cells were infected 
with gGag
+
 or gGag-.  When the cells reached confluence (~4 days), infectivity was 
quantified using the FIA with mAb 667 (envelope specific) and a fluorescently 
labeled secondary antibody. B). Mus dunni or Mus dunni/mA3 cells were infected 
with gGag
+
 or gGag- MuLVs and assayed as described in A). 
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extended passage.  To examine this possibility, serial cell-free passages of the gGag
+
 and 
gGag
-
 viruses were performed on normal and on mA3-expressing cell lines.      
 
 
 
 
 
 
 
 
 
 
 
 
 The passage experiments revealed no evidence of selection for effective 
replication in mA3 expressing cells.  Indeed, in cells expressing mA3 the gGag
-
 MuLV 
was virtually undetectable by passage four. In contrast, in passage experiments using cells 
not expressing mA3, the gGag
-
 virus persisted albeit at somewhat lower levels than the 
wild-type virus.    
2.3.3 Reporter assays 
 The FIA requires amplification of the initially infected cells, either by virus 
spread or cell replication, for efficient detection of focal infections
175
. The foci of the 
gGag
-
 virus on mA3 cells were smaller and more difficult to quantify than those observed 
Figure 2.4. Cell free serial passage of gGag
+
 and gGag
-
 on mA3 -/- and mA3 +/+ 
cells.   A). 3T3 and 3T3/mA3 cells were infected with each virus. 56 hours post 
infection the supernatants were transferred onto uninfected 3T3 and 3T3/mA3 cells. 
At the time of each transfer (pass) the supernatants were also transferred to Mus 
Dunni cells and assayed for infectivity. B). Mus dunni (Dunni) Mus dunni/mA3 
(Dunni mA3) cells were infected with each virus. 56 hours post infection the 
supernatants were transferred onto uninfected Mus Dunni and Mus dunni/mA3 cells. 
At the time of each transfer (pass) the supernatants were also transferred to Mus 
dunni cells and assayed for infectivity. Each experiment was repeated twice with 
three replicates. 
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on cells devoid of mA3.   Thus the difference in the number of foci scored in the FIA may 
have been due to differences in the initial infection of the cells or, alternatively, inhibition 
of virus spread occurring subsequent to infection. Infectivities of retroviruses are 
frequently quantified using retroviral vectors encoding a gene, such as alkaline 
phosphatase or β-galactosidase, whose expression is detectable in the infected target cells 
(reporter vectors).  Reporter vectors generally include retroviral LTRs, promoters, and a 
retroviral packaging signal in addition to the reporter gene.  They resemble a viral 
genome but do not encode viral structural proteins, thus infection by virions containing a 
reporter vector does not result in a productive infection capable of spread subsequent to 
the initial infection.  Foci scored using these viruses are developed by cell division and 
reflect the number of initial infectious events.   
 There are a number of procedures to generate retroviruses that have packaged 
reporter vectors.  The viruses can be generated by co-transfection of plasmids encoding 
virus structural proteins with plasmids encoding a reporter vector.  Alternatively, cell 
lines harboring a reporter genome can be infected with a MuLV resulting in the release of 
virions which have incorporated the reporter genome as well as the wild-type viral 
genome.  Two reporter genomes were utilized in these studies: LAPSN (Clontech 
Laboratories, Inc.) which encodes alkaline phosphatase and is expressed in the cytoplasm 
of infected cells and G1nβgSVNa
92
 which encodes β-galactosidase expressed in the cell 
nucleus.  Assays using either of these vectors yielded results similar to the FIA 
experiments suggesting inhibition of infectivity by cellular mA3 in a gGag-dependent 
manner.   
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 The quantification of infectivity of different viruses in single cycle reporter assays 
can be further refined by mixing viruses with different reporter genomes together and 
using the mixture to infect cells. This allows for a comparison of two viruses in precisely 
the same infection and effectively eliminates variables inherent in assays utilizing parallel 
cell cultures.  In these experiments mixtures of gGag
+
 and gGag
-
 virus stocks carrying 
distinct retroviral reporter genes were adjusted to give equal focus forming units (FFUs) 
and used to simultaneously assess both viruses in the same infection on 3T3 cells or 
3T3/mA3 cells. The results of these experiments corroborated the earlier findings 
regarding inhibition by cellular mA3 and are described in Chapter 3.     
Figure 2.5. Reporter gene assay. The reporter gene assay allows for the detection of 
infected cells through a non productive infection. The reporter genome is transcribed and 
integrated into the host genome, but does not encode viral structural proteins, and 
therefore expresses only the reporter enzymes. In the case of the LAPSN reporter 
genome, alkaline phosphatase is expressed and activity is detected in the cytoplasm. 
G1nβgSVNa encodes β-galactosidase that is expressed in the cell nucleus. Inset: Top: A 
focus of cells infected with MuLVs harboring the LAPSN reporter genome. Bottom: A 
focus of cells infected with MuLVs harboring the G1nβgSVNa reporter genome. Figure 
adapted from http://www.nimr.mrc.ac.uk/research/kate-bishop by Kate Bishop, used 
with permission. 
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2.4 Determination of virion-specific infectivity 
 Many studies have shown that hA3g is incorporated into HIV-1 ΔVif 
virions
23,100,126,128,141,173,179,182
. Some studies have also shown that mA3 is incorporated 
into the virions of MuLVs
100,100,188,188,203,203
. Incorporated A3 proteins affect the 
infectivity of the virions on target cells irrespective of whether they express mA3 or 
not
23,100,126,128,141,173,179,182
. Inhibition of infectivity by virion-associated mA3 would be 
reflected in a decrease in the specific infectivity of the virions.  In order to measure the 
affect of virion-associated mA3 on MuLV infectivity, virions were produced from mA3 
expressing cells as well as from cells not expressing mA3 and normalized to the number 
of virion particles by the quantification of reverse transcriptase (RT) activity.  This has 
been done in other studies
100,123,192,204
 using the enzymatic activity of the virion RT.  It is 
possible, however that the presence of mA3 in the virion may affect the RT activity 
rendering it an unreliable measure of virion quantity.  For this reason, the level of the 
major structural protein, p30, was estimated through immunoblotting procedures to 
provide an independent measure.  In all of the virus stocks generated in these studies, the 
RT activity reflected the level of p30.      
 The virions used for these studies were produced from mA3 expressing cells 
transduced with the LAPSN reporter genome and subsequently infected with the gGag
+
 
or gGag
-
 virus.  Stocks collected from these cells consist of virions that have packaged 
the reporter LAPSN genome or alternatively, the MuLV genome, enabling the assay of 
released viruses by either the reporter assay or the FIA.  Released virions were assayed 
for infectivity on Mus dunni cells.  The choice of Mus dunni cells was based on their 
permissiveness to infection with high efficiency by MuLVs.   In these experiments, the 
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titers of the viruses measured by the FIA were similar to titers measured by the alkaline 
phosphatase assay and the data from the two assays were combined. These experiments, 
described in chapter 3, indicated that virion-associated mA3 affected MuLV specific 
infectivity in a gGag-dependent manner.   
2.5 Determination of in vivo replication 
 Both cellular and virion-associated mA3 were shown to restrict infectivity of 
MuLVs in a gGag-dependent manner
101
. It was unknown, however, if mA3 exerted a 
similar effect in vivo. In order to determine if there was a gGag-dependent effect of mA3 
on MuLV replication in vivo, knock-out mouse strains in which the mA3 gene had been 
inactivated (mA3
-
/
-
) and their wild-type counterparts (mA3
+
/
+
) were utilized
164
.  Two 
mouse strains were examined in these studies. The 129/Ola strain predominately 
expresses the full-length mA3
164
 similar to the isoform utilized in the in vitro studies 
while the C57BL/6 strain predominantly expresses the delta exon 5 splice variant
164
. The 
C57BL/6 strains were included in the study because of the ease with which mouse 
colonies could be maintained compared to the 129/Ola strains.   Furthermore, analyses in 
C57BL/6 mice provide an assessment of the in vivo activity of a distinct mA3 isoform.  
 The absence of an antibody specifically reactive with mA3 makes the assessment 
of in vivo levels of the protein difficult.  mRNA measurements suggest that the 
expression of the protein increases during development and that mA3 expression is 
largely tissue-specific
159,164
.  With these considerations, the assessment of MuLV 
replication was accomplished at various times after infection by measuring viremia in the 
mice.  Viremia was measured with the expectation that it would more closely reflect total 
virus production in the animal than assays of particular tissues.  Viremia data for the 
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knock out and wild-type mouse strains supporting an in vivo effect of gGag on the action 
of mA3 is presented in Chapter 3.  
2.6 Protein analysis of infected cells and virions 
To determine expression of mA3 and viral proteins in the cell and virions, 
immunoblots of proteins resolved by electrophoresis on polyacrylamide gels (PAGE) 
were utilized. The rabbit gGag-antibody was initially provided in the form of antiserum
63
. 
Use of the antiserum presented background problems in the immunoblot procedure that 
was not corrected by increased incubation times in blocking reagents or by extensive 
washing. Further, the antiserum reacted poorly with HRP conjugated anti-rabbit 
antibodies tested. In attempts to alleviate these problems, IgG from the antiserum was 
purified using protein G and the IgG fraction directly conjugated with HRP. This 
procedure coupled with the addition of 5% rabbit serum to the standard blocking buffer 
markedly reduced the background seen with the anti-gGag antiserum.  Other antibodies 
used in these studies were also directly conjugated to HRP, which significantly reduced 
background.   
Immunoprecipitation of mA3 and viral proteins from lysates of cells or virions for 
immunoblot analysis was achieved with purified, unconjugated antibodies. In order to 
eliminate non-specific absorption of proteins to the protein G Dynal beads used in the 
immunoprecipitation experiments, beads were first bound to the antibody under 
saturating conditions. The bead/antibody complexes were then incubated in the presence 
of 10% BSA to minimize non-specific protein binding.  In addition, the lysates were pre-
absorbed with unconjugated protein G Dynal beads to reduce the level of non-specific 
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binding proteins. Immunoprecipitated complexes subjected to PAGE were analyzed by 
immunoblot procedures.    
The localization of mA3 and gGag in infected cells was determined by confocal 
microscopy.  During the course of these analyses it was found that sequential incubation 
of antibodies specific for HA-mA3 (rat) and gGag (rabbit) with the cells rather than 
incubation with a mixture of the antibodies yielded far superior images.  These primary 
antibodies were then detected by fluorescent goat anti-rat or anti-rabbit antibodies.  These 
analyses are presented in chapter 4.   
2.7 Localization of virion-incorporated mA3 and gGag  
 For determination of the localization of mA3 and gGag in the virion, virions 
purified by isopycnic centrifugation
54
 on sucrose gradients were applied to a 10-30% 
sucrose step gradient, with the 10% layer containing detergent to separate the outer 
membrane of the virion from the virion core. This procedure was adapted from 
previously reported methods to differentiate membrane components from the core 
components of various retroviruses including human, avian and murine 
retroviruses
3,136,140,162
.  The level of detergent was adjusted to eliminate the outer 
envelope protein from the sedimented core.  It is important to note that these conditions 
also resulted in the loss of substantial levels of the major structural core protein, in 
agreement with previously reported studies
3,136,140,162
.  These experiments revealed the 
presence of both gGag and mA3 in the virion core and are presented in chapter 4.   
2.8 Determination of G-to-A hypermutation 
 mA3 and hA3G both exhibit cytidine deaminase activity at the level of the single 
stranded transcripts produced during reverse transcription.  This process which results in 
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G-to-A mutations is thought to be a primary mechanism for retrovirus restriction
4,12,13
.  It 
was of interest to determine if this mechanism is operative in the restriction of MuLVs 
and if it is affected by the presence of gGag. To determine the rate of G-to-A mutation in 
the presence of cellular mA3, cells expressing or not expressing mA3 were infected with 
either the gGag
+
 or gGag
-
 MuLV.  A 24 hour time point after infection was chosen to 
avoid additional replicative cycles which would complicate the mutational analyses.  
After 24 hours, total DNA was harvested from the cell and the proviral DNA was 
amplified by PCR, cloned and sequenced to detect point mutations.   A similar 
methodology was used to determine the effects of virion-associated mA3.  In these 
determinations, virions produced from cells expressing or not expressing mA3 were used 
to infect Mus dunni cells. It is known that cells have evolved mechanisms to degrade 
uracil-containing DNA
18
.  It is possible that mutated transcripts might be eliminated by 
such a mechanism, yielding an underestimate of the actual incidence of mutations.  This 
possibility was addressed by determining the mutations in transcripts produced by viruses 
isolated from cells expressing or not expressing mA3. Transcripts were produced in cell-
free RT reactions with lysed virions, amplified by PCR, cloned and sequenced.  This 
procedure eliminated any possible effect of transcript elimination by cellular machinery; 
however, the analysis was limited to the action of virion-associated mA3.  In contrast to 
many other reported studies, the viral genome, rather than an artificial 
transcript
18,99,110,145
, was used to determine the mutation rate. To make sequence analysis 
comparable among all experiments, sequences of the PCR amplicons were trimmed to 
755 bp to minimize ambiguous sequence data and to ensure uniformity.  Although steps, 
such as biological cloning of the viruses, were taken to minimize pre-existing sequence 
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heterogeneity this is difficult to achieve with retroviruses due to the unedited replication 
of RNA viral genomes, Furthermore, amplification of a limited number of proviral 
transcripts could result in multiple clones of the same transcript which would contain the 
same mutations.  The probability of a base change occurring randomly in multiple clones 
at the same position is quite small.  Therefore, only those mutations found to be unique 
were considered in these analyses.  Mutation rates were calculated as the number of 
mutations per nucleotide sequenced and are presented in chapter 4. 
2.9 Determination of transcript levels 
 While deamination seems to be the main mechanism of action used by APOBEC3 
proteins to inhibit retroviral replication, other mechanisms have been observed. In HIV 
infection, cellular hA3G was shown to inhibit replication by inhibiting the initiation of 
reverse transcription
29
.  Similarly, no deamination activity was observed following 
infection by M-MuLV, however, the small inhibition of replication associated with mA3 
was attributed to a reduction of viral transcripts in the cell
18
.  As described in chapter 4, 
there was no significant difference in cytidine deaminase activity in the presence or 
absence of mA3 or gGag.  It is possible that mA3 affects viral replication by restricting 
the level of proviral synthesis in infected cells in a gGag-dependent manner.  To examine 
this possibility viral transcript levels in cells infected by either gGag
+
 or gGag
-
 MuLVs 
were quantified at 8 and 24 hours after infection by PCR.  Primers were employed that 
would specifically amplify the infecting viral sequences rather than endogenous retroviral 
sequences present in the mouse genome.  The results of these analyses indicate a gGag-
dependent reduction in viral transcript levels in the contexts of both cellular and virion-
associated mA3, and are described in chapter 4.  
 
38 
 
Chapter 3- The glycosylated Gag protein of a murine leukemia virus inhibits the 
anti-retroviral function of APOBEC3 
3.1 Abstract 
APOBEC proteins have evolved in both humans and mice as innate defenses 
against retroviral infections. To counteract the effects of human APOBEC3G, HIV has 
evolved the Vif protein.  Murine leukemia viruses (MuLVs) that infect and replicate in 
mice do not encode a Vif homologue and it has not been understood how they evade 
mouse APOBEC3 (mA3). We report here a MuLV that utilizes a glycosylated form of its 
gag protein (gGag) to counteract mA3.  gGag is critical for infection of mA3-expressing 
cell lines and for the infectivity of  released viruses which have encapsulated mA3.   
Finally, a gGag-deficient virus that is restricted for replication in wild-type mice 
replicates efficiently in mA3 knockout mice implying a novel role of gGag in 
circumventing the action of mA3 in vivo. 
 
Studies described in this chapter were published in Virology: 
Kolokithas, A., K. Rosenke, F. Malik, D. Hendrick, L. Swanson, M. L. Santiago, J. 
L. Portis, K. J. Hasenkrug, and L. H. Evans. 2010. The glycosylated Gag 
protein of a murine leukemia virus inhibits the antiretroviral function of 
APOBEC3. J Virol 84:10933-10936. 
3.2 Introduction 
APOBEC3G (hA3G) in humans and its mouse ortholog, APOBEC3 (mA3), act as 
potent innate defenses against retroviral infection.  Both proteins deaminate cytidine in 
single-stranded DNA ultimately resulting in hypermutation of newly synthesized proviral 
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DNA
28,110
, although additional deaminase-independent mechanisms of inhibition have 
been identified
4
.  Infectious exogenous retroviruses, including HIV and murine leukemia 
viruses (MuLVs), have evolved mechanisms to circumvent the action of the APOBEC 
proteins
12,28
.  HIV encodes the Vif protein which facilitates the rapid proteolysis of 
hA3G, while the mechanism by which exogenous MuLVs evade the action of mA3 is 
unknown
28
.  
Exogenous MuLVs, as well as some other gamma retroviruses, encode a 
glycosylated gag protein (gGag) originating from an alternate translation start site 
upstream of the methionine start site of the gag structural polyproteins
54,112,154
.  gGag is 
synthesized at similar rates and levels as the structural gag polyprotein in MuLV infected 
cells but is glycosylated and undergoes distinct proteolytic processing
65,133
.  A carboxyl 
fragment of gGag is released from the cell while an amino fragment is incorporated into 
the plasma membrane as a type 2 transmembrane protein
65,147
.  The functions of gGag 
remain unclear, but mutations that eliminate its synthesis severely impede in vivo 
replication of the virus with little, if any, effect on replication in fibroblastic cell 
lines
36,121,153
.     APOBEC3 proteins are expressed in many tissues in vivo but are poorly 
expressed in many in vitro cell lines
28
 suggesting a possible link between gGag 
expression and the evasion of mA3 by MuLVs.  These studies were undertaken to 
determine if the expression of the gGag protein facilitated MuLV replication in the 
presence of mA3 in vitro and in vivo.  
3.3 Materials and methods 
3.3.1 Plasmids, cells and viruses.   The plasmid encoding the full length mA3 
derived from the BALB/c mouse strain was a kind gift from Dan Littman
18
. It was 
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provided in the pcDNA3 vector and was tagged at the C-termini with hemagglutinin 
(HA)
18
.  NIH3T3 (3T3) and Mus dunni cells were maintained in Dulbecco‟s modified 
Eagle medium with 10% bovine serum and penicillin/streptomycin.  Quantitative RT 
PCR assays using the forward primer (ACCTGAGCCTGGACATCTTCA), the reverse 
primer (TGCAAAGATTCTGCTGGTTTTC) and the FAM-TAMRA probe 
(TCCCGCCTCTACAACATACGGGACC)  revealed that mA3 RNA was below the level 
of detection in both 3T3 and Mus dunni cells (data not shown).  Plasmid DNA was 
transfected into 3T3 or Mus dunni cells using lipofectamine (Life Technologies) 
according to the manufacturer‟s instructions and selected in media containing 1 mg/ml 
G418.  Single colonies of cells were transferred to new dishes and tested for their ability 
to stably express the C-terminal HA-tagged mA3 construct after ten passages. 3T3 and 
Mus dunni cells stably expressing the C-Terminal HA-tagged mA3 construct (3T3/mA3 
and Mus dunni/mA3 cells, respectively) were maintained in selection media.  CasFr
KP 
(gGag
+
) is an MuLV derived from the wild mouse ecotropic virus CasBrE and contains a 
short sequence of the F-MuLV, FB29, which includes the initiation site of the gGag 
protein 
152
.  CasFr--3+4 (gGag
-
) is a derivative of CasFr
KP
 in which mutations have been 
introduced to disrupt the expression of gGag
153
.  Mice were infected by intraperitoneal 
injection with approximately 2 x 10
5
 infectious units of virus within hours of birth.   
3.3.2 Virus isolation.  Virus was harvested from 3T3/mA3 cells  infected with 
either gGag
+
 or gGag
-
 viruses and purified by isopycnic gradient centrifugation as 
previously described
54
.   Briefly, supernatants were collected from infected cells and 
cleared of cellular debris by low speed centrifugation. Cleared supernatants were 
subjected to ultracentrifugation to pellet the virions. Pellets were resuspended in buffer 
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and placed on a 20 to 60% linear sucrose gradient for further ultracentrifugation. The 
fraction of the gradient containing virions was pelleted by ultracentrifugation, 
resuspended in a storage buffer and kept at -20C until used in further experimentation. 
3.3.3 Mice. The derivation of 129P2/OlaHsd mA3
-/- 
and C57BL/6 mA3
-/-
 mice 
has been previously described
164
.  C57BL/6 and 129P2/OlaHsd mice were obtained from 
Jackson Laboratories and Harlan Laboratories, respectively.  In the interest of brevity, 
129P2/OlaHsd will be referred to as 129/Ola mice throughout this article.  Mice were 
treated in accordance with the regulations and guidelines of the Animal Care and Use 
Committee of the National Institutes of Health.  
3.3.4 Assays of viral infectivity.  The quantification of viruses in single cycle 
infectivity assays was accomplished using the retroviral vectors LAPSN (Clontech 
Laboratories, Inc.) and G1nβgSVNa
92
.  Briefly, cells were plated in 60 mm tissue culture 
dishes, the cells infected the next day with virus and allowed to grow to confluence (3-4 
days).  Foci of cells expressing alkaline phosphatase or β-galactosidase were detected as 
previously described
92
 and counted as focus-forming units (FFU).   For mixed virus 
assays, vectors pseudotyped within gGag
+
 or gGag
-
 virions were harvested from 3T3 
cells that had been transduced with LAPSN or G1nβgSVNa.   Mixtures of gGag
+
 and 
gGag
-
 virus stocks carrying distinct retroviral vectors were adjusted to give equal FFUs 
and used to simultaneously assess both viruses in the same infection on 3T3 cells or 
3T3/mA3 cells.  For assays of progeny viruses released from 3T3 cells or 3T3/mA3 cells, 
the cell lines were transduced with the LAPSN vector and subsequently infected with a 
gGag
+
 or gGag
-
 MuLV.  The levels of progeny virus were assessed on Mus dunni cells 
and were normalized for reverse transcriptase activity using a colormetric reverse 
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transcriptase kit (Roche) according to the manufacturer‟s instructions. Reverse 
transcriptase activity was expressed as the absorbance at 405nm per ml.  The infectivity 
of progeny virus released from 3T3 or 3T3/mA3 cells was also quantified using a 
monoclonal antibody (mAb) specifically reactive to the envelope protein of the viruses, 
mAb 667
127
, in focal immunofluorescence assays
175
.   
3.3.5 Immunoblotting.  After virus isolation, samples were lysed in Protein 
Extraction reagent Type 4 (Sigma) and incubated for 10 minutes at room temperature.   
For cell lysate samples, monolayers were lysed by addition of lysis buffer (0.01M 
NaH2PO4 [pH 7.6], 0.001M EDTA, 1% Triton X-100, 0.1 % SDS).  Cell lysates harvested 
from the plates were centrifuged at 13,000 x g for 10 minutes to separate the soluble and 
insoluble fractions. The soluble protein fraction was used to measure total protein 
concentration in the sample using a Bradford assay (Pierce) according to the 
manufacturer‟s protocol. Samples were normalized according to their protein 
concentrations and were adjusted to 1X Laemmli sample buffer containing 5% β-
mercaptoethanol and boiled for 10 minutes. The samples were then subjected to SDS-
PAGE (10% acrylamide, Life Technologies), followed by transfer onto PVDF 
membranes. Western Blot analysis was performed by probing with monoclonal anti-HA 
horseradish peroxidase (HRP)-conjugated antibody (Roche), polyclonal rabbit anti-gGag 
HRP-conjugated antibody or an HRP-conjugated monoclonal anti-p30 antibody (mAb 
18-7)
25
.  Membranes were stripped using 62.5 mM Tris-HCl, pH 6.8, 100 mM β-
mercaptoethanol, 2% SDS for 30 minutes at 55
o
 C on a rotary shaker. The anti-gGag 
antibody and the monoclonal anti-p30 antibody were purified using a HiTrap protein G 
HP affinity column (GE Healthcare) according to the manufacturer‟s instructions. 
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Figure 3.1.  Effect of cellular mA3 on infection by gGag
+
 or gGag
-
 MuLVs.    
3T3 and 3T3/mA3 cells were infected with mixtures of gGag
+
 and gGag
-
 viruses, each 
carrying a distinct retroviral vector encoding either alkaline phosphatase (LAPSN) or β-
galactosidase (G1nβgSvNa) and assayed by scoring FFU of cells expressing the 
respective enzymes.  The mixtures were adjusted to give equivalent titers of alkaline 
phosphatase and β-galactosidase on 3T3 cells. Statistical analysis was performed using 
the unpaired Student's
 
t test. 
Antibodies were conjugated to HRP using a Lightning-Link HRP conjugation kit (Innova 
Biosciences) according to the manufacturer‟s instructions.   
3.4 Results 
3.4.1 Efficient infection of mA3-expressing cells is dependent on gGag.  
Several reports of the effects of mA3 proteins on virus replication have examined the 
infectivity of virions released from cells transfected with cloned proviral DNA in the 
presence or absence of mA3
51,110,162
.   Such analyses do not test effects of mA3 present in 
the cytoplasm of the cells on the infectivity of MuLVs that have not been previously 
exposed to mA3.  To address this issue we developed a 3T3 cell line that expressed an 
HA-tagged mA3 protein  (3T3/mA3).  The infectivity of the gGag
+
 and gGag
-
 MuLVs 
was compared on 3T3 and 3T3/mA3 cells using mixtures of the viruses, each carrying a 
distinct retroviral vector encoding either alkaline phosphatase (LAPSN) or B-
galactosidase (G1nBgSvNa).  Utilizing mixtures of viruses with different readouts  
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for infectivity enabled the assessment of the effects of cellular mA3 on both viruses in 
precisely the same infection.  
Experiments were performed using both MuLV/vector combinations (i.e., 
LAPSN(gGag
+
 MuLV) plus G1nβgSvNa(gGag
-
 MuLV) or alternatively, 
G1nβgSvNa(gGag
+
 MuLV) plus LAPSN(gGag
-
 MuLV)).  These analyses indicated that 
cellular mA3 exerted a marked inhibitory effect on the infectivity of gGag
-
 virus but not 
on the gGag
+
 virus (Figure 3.1).  
3.4.2 Both gGag
+ 
and gGag
-
 MuLVs incorporate mA3 into progeny virions.  A 
number of studies have reported partial inhibition of ecotropic MuLVs as a result of 
incorporation of mA3 into progeny virions
110,123,162,188
.  Indeed, it has been suggested that 
MuLVs may evade the action of mA3 by exclusion of the protein from virions, although 
there are conflicting accounts regarding this matter
18,43,100,110,145,162
.  To determine if the 
presence of  gGag influenced the incorporation of mA3, virions were isolated from mA3 
cells infected with gGag
+
 or  gGag
-
 MuLVs and examined by immunoblot analyses.  mA3 
was readily detected in both virus preparations with no discernible differences in the 
levels of virion incorporation in  gGag
+
 or  gGag
-
 MuLVs (Figure 3. 2A).  This result is in 
agreement with other reports that have shown incorporation of mA3 into virions 
18,100,145,162
.  Furthermore, gGag was also found to be incorporated into virions (Figure 
3.2B) consistent with an earlier study
63
.   
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Figure 3.2.  Infectivity of virions released from 3T3 or 3T3/mA3 cells infected with 
gGag
+
 or gGag
-
 MuLVs.   
Virions released from 3T3/mA3 cells infected with gGag
+
 or with gGag
-
 were analyzed 
by immunoblotting for the presence of mA3 or gGag.   A). Immunoblot analysis of 
gGag
+
 virions, gGag
- 
virions and a 3T3/mA3 cellular lysate for the presence of mA3 
using a HRP-conjugated anti HA antibody.  The 3T3/mA3 cellular lysate was included 
as a comparison of mA3 in the cells to that in the virions.  The blot was also developed 
with a HRP-conjugated monoclonal antibody to p30 as a loading control. Exposure 
times for detecting mA3 were approximately 10-fold longer than for p30.   B). 
Immunoblot analysis of gGag
+
 or gGag
-
 for the presence of gGag using a HRP-
conjugated anti gGag antibody.  The blot was subsequently stripped and developed 
with an HRP-conjugated monoclonal antibody to p30 as a loading control.  Exposure 
times for detection of gGag were approximately 20-fold longer than for p30.  C). 3T3 
cells or 3T3/mA3 cells harboring the retroviral vector LAPSN were infected with 
gGag
+
 or gGag
-
 MuLVs.  Infectivity of progeny virions was assessed on uninfected M. 
dunni cells by alkaline phosphatase assays and by FIA. Infectivity titers, expressed as 
FFUs were normalized to the number of virions by assessing reverse transcriptase 
activity (RT).  RT was expressed as the absorbance per ml at 405nm.  Statistical 
analysis was performed using the unpaired Student's
 
t test.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.3 Virion-associated mA3 selectively inhibits gGag
-
 MuLV infectivity. To 
determine if virion-incorporated mA3 differentially influenced gGag
+
 and gGag
-
 MuLVs 
we examined the infectivity of viruses released from 3T3/mA3 cells as well as from 3T3 
cells lacking mA3.  Both cell lines were transduced with the retroviral vector, LAPSN, 
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which encodes alkaline phosphatase to enable the quantification of progeny virus 
infectivity in single cycle assays.  Cells were infected with gGag
+
 or gGag
-
 MuLVs and 
released viruses were quantified in assays on Mus dunni cells. Infectivity was normalized 
to the relative number of virus particles by quantifying reverse transcriptase activity.  
Considering that the reverse transcriptase activity included virions carrying the retroviral 
vector as well as virions carrying the MuLV genome, the infectivity of progeny virus 
released from 3T3 or 3T3/mA3 cells was also quantified using a monoclonal antibody 
specifically reactive to the envelope protein of the viruses in focal immunofluorescence 
assays.  The retroviral vector assays and the fluorescence assays closely paralleled one 
another and the results were combined (Figure 3.2C).  These analyses revealed that the 
infectivity of gGag
-
 virus released from 3T3/mA3 cells was markedly decreased 
compared to gGag
-
 virus released from 3T3 cells.  In contrast, no significant differences 
were observed in the infectivity of gGag
+
 virus released from 3T3/mA3 and 3T3 cells 
(Figure 3.2C).  Experiments using a Mus dunni cell line expressing the mA3 protein to 
assess the effects of cellular as well as virion-incorporated mA3 on the infectivity of 
gGag
+
 and gGag
-
 MuLVs yielded similar results (data not shown).  
3.4.4 mA3-deficient mice support the replication of gGag
+
 and gGag
-
 MuLVs.  
If mA3 restriction is a major factor influencing in vivo replication of MuLVs and its 
action is sufficiently repressed by gGag, it would be expected that mice lacking mA3 
would be permissive to infection by both gGag
+
 and gGag
-
 MuLVs.   To examine this 
possibility we determined the level of replication of gGag
+
 and gGag
-
 MuLVs in mA3 
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Figure 3.3.  Replication of gGag
+
 or gGag
-
 MuLVs in wild type and mA3 knockout 
mice.   
A). 129/Ola wild type (mA3
+/+
) or 129/Ola mA3 knockout (mA3 
-/-
) mice were inoculated 
with gGag
+
 or gGag
-
 MuLVs. Three weeks after infection the mice were sacrificed, sera 
collected and viruses quantified by a focal immunofluorescence assay on M. dunni cells. 
n=9 for gGag
+
 MuLV in mA3
+/+
 mice, n=9 for gGag
+
 MuLV in mA3
-/-
mice, n=7 for gGag
-
 
MuLV in mA3
+/+
 mice and n=14 for gGag
-
 MuLV in mA3
-/-
 mice.  Statistical analysis was 
performed using the unpaired Student's
 
t test. B). C57BL/6 wild type mice (mA3
+/+
) or 
C57BL/6 mA3 knockout mice (mA3
-/-
) were inoculated with gGag
+
 or gGag
-
 MuLVs.  
Three weeks after infection the mice were sacrificed, sera collected and viruses quantified 
by focal immunofluorescence assays on M. dunni cells.  Each point represents the level of 
viremia from an individual animal with n=6 for the gGag
+
 MuLV in mA3
+/+
 mice, n=7 for 
the gGag
+
 MuLV in mA3
-/-
 mice, n=9 for the gGag
-
 MuLV in mA3 
+/+
 mice and n=11 for 
the gGag
-
 MuLV in mA3
-/-
 mice.  Wilcoxon Signed rank test was used to differentiate 
whole number integers from zero values.  The unpaired Student‟s t test was used to 
compare non-zero results.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
knockout mice (mA3
-/-
) and their wild type counterparts (mA3
+/+
). Comparisons of the 
replication of gGag
+
 and gGag
-
 MuLVs revealed a clear influence of 129/Ola mA3 on 
their replication (Figure 3.3A).   In agreement with previous studies on the replication of 
gGag-deficient mutants
36,123,153
, the replication of the gGag
-
 MuLV was severely 
restricted in normal 129/Ola mice.  However, in 129/Ola mice lacking mA3, the gGag
+
 
and gGag
-
 MuLVs replicated to equally high levels. These results indicate that the 
inability of the gGag
-
 MuLV to replicate efficiently in vivo is the result of mA3 
expression.   
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C57BL/6 mice contain the  Fv1
b
 allele
181
.  The MuLVs used in this study are N-
tropic, thus the levels of replication of the MuLVs in C57BL/6 mice were much lower 
than in the 129/Ola mice, which contain the Fv1
n
 allele (Figure 3.3B)
181
.  Nevertheless, 
replication in these mice was sufficient to observe mA3 inhibition in a gGag-dependent 
manner.  Replication of the gGag
+
 MuLV was easily detectable in both C57BL/6 mA3
+/+
 
and mA3
-/-
 mice, while replication of the gGag
-
 MuLV was below the level of detection 
in the wild-type C57BL/6 mA3
+/+
 mice.  However, in C57BL/6 mA3
-/-
 mice, the gGag
-
 
MuLV replicated to the same level as the gGag
+
 MuLV.   Thus, the inability of the gGag
-
 
MuLV to replicate in vivo in C57BL/6 mice is the result of mA3 expression, similar to 
our findings using 129/Ola mice.  It is noteworthy that C57BL/6 mice predominantly 
express a splice variant mA3 mRNA which lacks exon 5 while 129/Ola mice 
predominantly express a complete mA3 mRNA.  Assuming that the mRNAs are 
translated with equal efficiencies, our results indicate that the MuLV gGag studied here is 
able to suppress the antiviral effect of both the full-length and exon 5-deleted proteins.   
3.5 Discussion 
Nearly all exogenous MuLVs contain sequences encoding gGag which is 
synthesized from an alternate initiation site upstream of the start site of the gag 
polyprotein
48,154
.  Although studies have found gGag to be necessary for in vivo 
replication, the basis for this effect was unknown
36,121,153
.  Moreover, the means by which 
exogenous MuLVs evade the action of mA3 was unclear
28,162
.  Our results establish a 
novel role of gGag as an antagonist of mA3 thereby providing insight into both of these 
questions.   
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We observed gGag-dependent inhibition by mA3 in two distinct contexts: 
inhibition of infectivity by mA3 expressed in the cell as well as inhibition by virion-
associated mA3.  Interestingly, it was recently reported that infection by Moloney MuLV 
(M-MuLV) was partially inhibited by mA3 and that both virion and cellular mA3 
contribute to the inhibition
123
. Inhibition of infection by both virion and cellular mA3 has 
also been observed with mouse mammary tumor virus
138
.  Furthermore, HIV has also 
been reported to be inhibited by cytoplasmic hA3G
196
.   
It is somewhat surprising that cellular mA3 exerts a gGag-dependent effect on 
infecting MuLVs.  The level of gGag incorporated into virions is low compared to the 
structural proteins but clearly detectable.  Furthermore a previous study of the gGag
+
 
MuLV utilized here indicated that gGag is indeed a component of the virion
63
.  Virion-
associated gGag may directly influence the action of cellular mA3.  Alternatively, the 
susceptibility of the gGag
-
 MuLV to cellular mA3 may occur by an indirect mechanism.  
In this regard, it has been reported that gGag is involved in virion release and that gGag
-
 
M-MuLV exhibits an abnormal morphology during virion budding
121
.  It is conceivable 
that mature virions may also be altered from an mA3-resistant to an mA3-susceptible 
phenotype.    
We observed that progeny virions released from mA3 expressing cells were also 
inhibited in a gGag-dependent manner.  While the level of gGag incorporated into virions 
is low, in infected cells the rate of synthesis and the level of gGag are comparable to that 
of the unglycosylated Gag polyprotein precursor
54
.  It is possible that gGag counteracts 
the action of mA3 on progeny virions by a mechanism distinct from the effect of virion-
associated gGag on cellular mA3 discussed above.  Although both gGag
+
 and gGag
-
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MuLVs incorporate mA3 into virions at similar levels we have not determined if this 
incorporation is qualitatively the same with both MuLVs.  It is possible that the virion-
associated mA3 is altered in its location or association with virion components in the 
gGag
+
 MuLV.  Such an alteration could be influenced by an interaction of the newly 
synthesized gGag with mA3 in the cell.  The mechanism(s) by which gGag influences the 
action of mA3 awaits further investigation.   
A very recent report indicates that gGag exhibits some functional similarities  to 
the  Nef protein of HIV
149
.  Nef is an accessory protein of HIV and SIV that exhibits an 
incredibly complex range of functions that include down regulation of CD4 and MHC 
proteins
67,169
, induction of apoptosis
68
 and increasing efficiency of reverse 
transcription
168
.  Nef is incorporated into virions facilitating infectivity and in vivo 
replication
19,94,95,144
, however an influence of Nef on the action of APOBEC3 proteins has 
not been described.  It is quite possible that gGag, like Nef, has more than one function in 
the virus life cycle.    
Our analyses indicated that mA3 did not inhibit the gGag
+
 MuLV, however a 
number of studies have reported partial to marked inhibition of other  MuLVs
110,123,162,188
, 
all of which encode a gGag protein.  A direct comparison of the inhibitory effects of mA3 
on M-MuLV and the ecotropic AKV MuLV revealed that  AKV was inhibited to a greater 
extent than M-MuLV
110
.  Furthermore, inhibition of M-MuLV by mA3 was not 
accompanied by G-to-A  mutations in newly synthesized DNA
110,162
, whereas inhibition 
of AKV by mA3 exhibited extensive G-to-A mutations
110
.  Differences in the 
susceptibility of MuLVs to inhibition by mA3 could reflect differences in the efficacy of 
their respective gGags to counteract mA3.  In this regard, a comparison of the gGag 
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sequences of M-MuLV and AKV reveals extensive amino acid differences in their amino-
terminal fragments (data not shown).   
 A xenotropic murine leukemia–like retrovirus (XMRV) has been found in human 
prostate cancer tissue as well as in cohorts of patients diagnosed with chronic fatigue 
syndrome 
59,120,166,193
.   Recent studies have reported that mA3 inhibits the replication of 
XMRV to a much greater extent than M-MuLV
74,145
.  It is noteworthy that all XMRV 
isolates exhibit a termination codon in the coding sequences of gGag resulting in a 
truncation of the protein just before the transmembrane region
193
.  Thus, the sensitivity of 
XMRV replication to mA3 may reflect the absence of a functional gGag.    
In agreement with earlier studies, we observed a marked inhibition of in vivo 
replication of the gGag
-
 MuLV compared to the gGag
+
 MuLV.  Levels of the gGag
-
 
MuLV were restored to the high levels observed with the gGag
+
 MuLV in 129/Ola KO 
mice lacking mA3.  These results further substantiated the role of gGag as an antagonist 
of the restriction factor.  Similar results were observed with C57BL/6 mice with the level 
of replication of the gGag
-
 MuLV reaching levels observed for the gGag
+
 MuLV in mA3
-/-
 
mice.  The level of replication of the gGag
+
 MuLV in C57BL/6 mA3
+/+
 mice was low due 
to Fv1 restriction and was not significantly increased in C57BL/6 mA3
-/-
 mice.  This 
result differs from studies of M-MuLV replication in C57BL/6 mA3
-/-
 mice indicating 
enhanced MuLV replication compared to replication in  C57BL/6 mA3
+/+
 mice
123
.  In 
contrast to M-MuLV, which is moderately inhibited by mA3
110,123,162
, the gGag
+
 MuLV 
utilized in this study was not inhibited.  This difference would account for the increased 
replication of M-MuLV in the absence of mA3.   
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These studies provide at least partial answers to two difficult questions in 
retrovirology: those of the function of the gGag of MuLVs and the means by which 
MuLVs evade the action of APOBEC3. Although the gGag of exogenous MuLVs 
provides a similar function as the Vif protein of HIV, further studies are required to 
determine similarities and differences in their mode of action.  Such studies are 
particularly relevant in light of recent reports indicating cross-species retroviral infections 
from mouse to humans
120,166,193
.   
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Chapter 4-The Murine leukemia virus gGag protein facilitates reverse transcription 
in the presence of murine APOBEC3 
4.1 Abstract 
Humans and mice have evolved APOBEC proteins that act as innate defenses 
against retroviral infections. We have recently reported that a MuLV utilizes a 
glycosylated form of its Gag protein (gGag) to effectively inhibit the antiviral activity of 
murine APOBEC3 (mA3) in vitro. Our results indicated that gGag-dependent inhibition 
by mA3 occurs in two different contexts: cellular mA3, which inhibits initial infection of 
the cell by MuLVs not previously exposed to mA3; and virion-associated mA3, present in 
progeny MuLVs released from cells expressing mA3. Infection by MuLVs containing 
mA3 is inhibited irrespective of the expression of mA3 in the target cells.  The 
mechanism by which gGag is protective against mA3 is unknown. To counteract the 
human APOBEC3G (hA3g), HIV has evolved the Vif protein, which depletes hA3g from 
infected cells by facilitating its degradation through the proteosome. We report here that a 
gGag-containing MuLV does not deplete mA3 from an infected cell. Further, 
immunoprecipitation and localization experiments suggest that mA3 does not interact 
with gGag directly in an infected cell.  In contrast, both gGag and mA3 are associated 
with the virion core and are coprecipitated in the context of the mature virions. Both 
hA3g and mA3 have been reported to use deamination-dependent and -independent 
mechanisms to inhibit retroviral replication. Inhibition by mA3 on gGag-deficient virions 
correlates with a decrease in the level of transcripts upon infection of cells and appears 
largely independent of deamination activity.  
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4.2 Introduction  
APOBEC3s (hA3G in humans, mA3 in mice) are cytidine deaminases that act on 
single-stranded DNA during reverse transcription resulting in hypermutation of newly 
synthesized proviral DNA
28,110
. HIV-1 has a gene product, Vif, to counteract hA3G 
antiviral effects. Vif binds to the N-terminal of hA3G and recruits a ubiquitin ligase 
complex that marks hA3G for destruction in the proteasome
34
. Vif has also been shown to 
impair the translation of hA3G mRNA
128
 and prevent encapsulation by binding to 
hA3G
141
. MuLVs are largely insensitive
13
 to the actions of murine APOBEC3 (mA3), 
although this has recently become a point of controversy
18,43,100,110,145,162
. It appears that 
MuLVs escape mA3 activity without a Vif-like accessory protein. 
APOBEC3 family members from both humans and mice inhibit endogenous LTR 
retrotransposons and retroviruses
12,49,50
. A major difference between exogenous and most 
endogenous MuLVs in the mouse is the absence of a sequence for the expression of 
gGag. The gGag protein is translated from the same viral mRNA as Gag, but uses a CUG 
start codon that is upstream of the AUG start codon for Gag
54,65,133
 resulting in an 
additional 88 amino acids on the N-terminus of Gag. The protein is then targeted to the 
rough endoplasmic reticulum for glycosylation and is subsequently exported to the cell 
surface
65,147
 where it is cleaved in the CA domain. Some of the C-terminal portion of 
gGag is secreted whereas some of the N-terminal portion adopts a type II integral 
membrane configuration
65,147
. The amounts of Gag and gGag synthesized in infected cells 
are similar, however the amount of gGag  incorporated into the virion is low compared to 
other Gag structural proteins
65
. MuLVs require gGag for efficient replication  in vivo and 
it is a major determinant of virulence 
65
. However, gGag is not required for efficient in 
 
55 
 
vitro replication, as the mutant viruses that lack gGag are able to replicate in cell lines 
with similar efficiency to their wild-type counterparts
63,65,121
. In a recent report we 
observed that mA3 suppresses the replication of a gGag
-
 virus compared to a gGag
+
 virus 
both in vitro and in vivo, however the mechanism by which gGag exerts this effect is 
unclear.  The present studies were undertaken to investigate possible mechanisms by 
which gGag evade the action of mA3. 
4.3 Materials and Methods 
4.3.1 Plasmids, cells and viruses.   The maintenance of cell lines, the derivation 
of cells expressing mA3 by transfection of plasmids and the use of viruses in this study 
were as described in chapter 3.3.1. 
4.3.2 Virion core isolation.  Total virion isolation is described in chapter 3.3.2.   
For isolation of viral cores, a suspension of purified virions was sedimented through a 10-
30% sucrose step gradient in PBS containing 5% IGEPAL, in the 10% sucrose layer of 
the gradient.  The gradients were centrifuged at 30,000 rpm for 1.5 hours after which the 
pellets were resuspended in Laemmli sample buffer containing 5% β-mercaptoethanol 
and samples were incubated in a boiling water bath for 10 minutes. 
4.3.3 Immunoblotting.  Immunoblotting procedures were performed as described 
in chapter 3.3.5. 
4.3.4 Determination of cellular mA3 levels. The effect of infection on the levels 
of cellular mA3 was examined in 3T3/mA3 cells infected with either gGag
+
 or gGag
- 
MuLVs. Forty-eight hours after infection, cells were harvested and analyzed by 
immunoblot analysis. The level of mA3 was normalized by comparing its signal intensity 
to GAPDH or b-Actin signal intensity using ImageQuant software (GE).  
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4.3.5 Immunoprecipitation. Purified virions were lysed in 50 mM Tris, 80 mM 
potassium chloride, 0.75 mM EDTA and 0.5% Triton X-100, pH 7.8, and incubated for 
30 minutes at room temperature.   Confluent monolayers of cells were lysed by addition 
of Cell lytic M cell lysis reagent (Sigma).  Cell lysates harvested from the plates were 
centrifuged at 13,000 x g for 10 minutes to separate the soluble and insoluble fractions.  
The total protein concentration in the soluble fraction was determined using a BCA assay 
(Pierce) according to the manufacturer‟s protocol. Samples were normalized according to 
their protein concentrations. Protein G Dynal beads (Invitrogen) were incubated in the 
presence of monoclonal anti-HA antibody (Roche), polyclonal rabbit anti-gGag antibody 
or a monoclonal anti-p30 antibody (mAb 18-7). The bead/antibody mixtures were then 
incubated with BSA to block non-specific binding.   The blocked bead/antibody mixtures 
were added to lysates which had been pre-cleared with unconjugated protein G beads and 
incubated on a rotating platform for 1hr at 4C.  The incubated beads were washed with 
PBS five times and bound proteins were eluted by the addition of 1X Laemmli sample 
buffer containing 5% β-mercaptoethanol and incubating in a boiling water bath for 10 
minutes. The samples were then subjected to SDS-PAGE (10% acrylamide, Life 
Technologies), followed by electrophoretic transfer onto a PVDF membrane. 
4.3.6 Mutational Analyses. The effect of cellular mA3 on the mutation of viral 
transcripts was assessed in 3T3 or 3T3/mA3 cells infected with either gGag
+
 or gGag
-
 
MuLVs that had been biologically cloned by endpoint dilution using the FIA (Chapter 3).  
Cells were infected with the respective viruses and twenty-four hours after infection the 
cells were lysed and newly synthesized viral sequences amplified using the Extract and 
Amp PCR kit (Sigma) according to the manufacturer‟s instructions.  The primers used for 
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amplification were the env gene primers with CasFrKP6805 
(TTGAGAGAGTACACTAGTC) as the forward primer and CasFrKP7886RC  
(TCTGTTCCTGACCTTGATC) as the  reverse primer.  PCR products were resolved on a 
3% 3:1 NuSieve agarose gel and were purified using a Zymo gel purification kit (Zymo) 
according to manufacturer‟s instructions. Purified PCR products were cloned into the 
PCR4-TOPO vector using the TOPO TA Cloning Kit for Sequencing (Invitrogen) 
according to the manufacturer‟s instructions and sequenced using the env primers.  For 
virion mutation analysis, virions were harvested from tissue culture supernatant of 3T3 or 
mA3/3T3 cells infected with the gGag
+
 or gGag
-
 viruses. The transcripts from lysed 
purified virions were generated using the Colormetric reverse transcription kit (Roche). 
Reaction conditions were followed according to the manufacturer's instructions; however, 
random hexamers and unlabeled nucleotides were used in place of the primers and 
nucleotides provided with the kit.   Transcripts generated in this reaction originated from 
the virion RT with the virion genome as the template.    The transcripts were amplified, 
purified, cloned and sequenced as described above. The influence of virion-associated 
mA3 on the mutation of viral transcripts was assessed after infection of naive Mus dunni 
cells with gGag
+
 or gGag
-
 viruses harvested from 3T3 or 3T3/mA3 cells.   Twenty-four 
hours after infection the Mus dunni cells were lysed and viral sequences amplified, 
purified, cloned and sequenced as described.   
Groups of sequences generated in these analyses were compiled and compared in 
the DNAstar Lasergene program, SeqMan. All sequences were trimmed from either end 
to minimize ambiguity and to yield a 755 bp sequence for uniform comparisons.   
Redundant mutations occurring at the same position in two or more clones likely 
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originated from pre-existing heterogeneity in the virus stock or by amplification of the 
same proviral transcript (see chapter 2).  Therefore, coincident mutations were eliminated 
from the analysis.  Mutation rates for each type of point mutation (e.g., G-to-A 
transitions) were calculated as the frequency per nucleotide of that change in each 
sequenced clone.  The mutation rates for each type of mutation for each clone were 
averaged to give the mean mutation rate as well as the standard error for that specific type 
of mutation.  The overall mutation rate per clone was calculated as the frequency per 
nucleotide of all mutations in each clone.  The overall mutation rate for the data set was 
calculated by averaging the rate for each clone to give the mean overall mutation rate and 
the standard error.   
4.3.7 Accumulation of proviral transcripts in infected cells.  To determine the 
effect of cellular mA3 on reverse transcription, 3T3 and 3T3/mA3 cells were infected 
with gGag
+
 and gGag
-
 viruses.  Cellular DNA was isolated at eight and twenty-four hours 
post-infection using the AquaGenomic DNA isolation kit (Aquaplasmid) according to the 
manufacturer‟s instructions.  Levels of viral- specific DNA were then determined by 
semi-quantitative PCR using primers specific for the viral env gene (CasFrKP6805 and 
CasFrKP7886RC). PCR products of the gapdh gene were amplified using Gapdh-152f 
AACGACCCCTTCATTGAC (forward) and Gapdh-342r TCCACGACATACTCAGCAC 
(reverse) and used as internal controls. Evaluation of the influence of virion-associated 
mA3 on the level of transcripts in infected cells was assessed by infection of naïve Mus 
dunni cells with gGag
+
 and gGag
-
 viruses harvested from 3T3 or 3T3/mA3 cells.  DNA 
from infected cells was isolated and evaluated for viral transcript levels as described 
above.  In these experiments Mus dunni cells were infected with virus stocks normalized 
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using the major structural virion protein, p30.  A standard dilution curve was generated 
using amplification of a plasmid containing the sequence of the gGag
+
 MuLV with the 
env gene primers. The standard dilution curve was used to quantify transcript levels by 
densitometry using the AlphaView software program (Cell Biosciences).  
4.3.8 Localization of gGag and mA3 in infected cells. 3T3 or 3T3/mA3 were 
seeded on cover slips and infected with gGag
+
, gGag
-
 MuLVs, or mock-infected. Samples 
were collected at 6, 12, 24, and 48 hours post infection.  Cells were fixed for 15 minutes 
in 3.7% formaldehyde, washed in PBS, and permeabilized in 0.5% Triton X-100 for 15 
minutes. Samples were blocked with 10% BSA in PBS for 30 minutes, followed by 
incubation for 30 minutes with monoclonal rat anti-HA (1:100) and a 30 minute 
incubation with polyclonal rabbit anti-glycosylated gag (1:250) in 3% BSA in PBS. 
Samples were then washed in PBS and incubated with DylightFluor (Jackson 
Laboratories) 488-conjugated goat anti-rat IgG (1:250) and DylightFluor (Jackson 
Laboratories) 594-conjugated goat anti-rabbit IgG (1:250) with Hoechst 33342 
(1:100,000) as a nuclear counterstain. Samples were washed in PBS followed by rinsing 
in ddH2O. Processed coverslips were mounted onto slides with Mowiol (Polysciences) 
and fluorescence images were collected via sequential scanning on a Zeiss 510 Meta 
scanning laser confocal microscope. 
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4.4 Results 
4.4.1 mA3 is not depleted from infected mA3 cells in a gGag-dependent manner  
 In a previous report we observed that mA3 inhibited the replication of a gGag
-
 
virus but not a gGag
+
 virus
101
. The Vif protein of HIV blocks the action of hA3G by 
inducing its rapid proteolytic degradation through ubiquitination and transport to the 
proteosome
34
.  It was therefore of interest to determine if MuLVs utilize a similar 
mechanism to counteract the antiviral activity of mA3.  3T3/mA3 cells were infected 
with either gGag
+
 or gGag
-
 MuLVs. Forty-eight hours after infection, cells were 
harvested and mA3 levels evaluated by immunoblot analysis. The levels of mA3 were 
quantified by comparing signal intensities of mA3 to GAPDH or β-Actin signal 
intensities using ImageQuant software (GE).  
 
 
 
 
 
 
A reduction in the level of mA3 was not observed in gGag
+
 MuLV infected 3T3/mA3 
cells compared to cells infected with the gGag
-
 virus or mock infected cells (Figure 4.1), 
indicating that mA3 is not depleted from infected cells in a gGag-dependent manner.  
4.4.2 Interactions between gGag and mA3 are not detected in infected cells  
 The MuLV gGag protein is synthesized to levels equivalent to the structural Gag 
proteins in infected cells
54
 and may serve to bind and deactivate mA3.  To determine if 
there are binding interactions between mA3 and gGag in infected cells, 3T3/mA3 cells 
Figure 4.1. Determination of depletion in 
infected 3T3/mA3 cells. 3T3/mA3 cells were 
infected with either gGag
+
 or gGag
-
. Forty-
eight hours after infection, cells were harvested 
and analyzed via immunoblot analysis. The 
amount of depletion was quantified by 
comparing signal intensity to β-Actin signal 
intensity using ImageQuant software (GE).  
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Figure 4.2. Immunoprecipitation of infected 
3T3/mA3 cells.  Infected 3T3/mA3 cell lysates 
were immunoprecipitated with a monoclonal 
anti-HA antibody or the polyclonal rabbit anti-
glycosylated gag antibody. Immunoprecipitated 
samples were eluted by addition of running 
buffer and boiling for 10 minutes. The samples 
were then subjected to SDS-PAGE followed by 
transfer onto PVDF membranes. Membranes 
were analyzed by immunoblot technique. 
were infected with either gGag
+
 or gGag
-
 MuLVs or mock-infected. Forty-eight hours 
after infection, cells were lysed and immunoprecipitated with anti-HA or anti-gGag 
antibodies. Immunoprecipitated complexes were analyzed by immunoblot analysis. Both 
of the antibodies precipitated their respective proteins, however, coprecipitation of mA3 
and gGag was not observed with either antibody in lysates of infected 3T3/mA3 cells 
(Figure 4.2).  
 
 
 
 
 
 
 
 
 
 
 
 
4.4.3 Localization of mA3 and gGag in infected cells  
 It is possible the reaction conditions used in the immunoprecipitation reactions 
may disrupt weak interactions or that interactions between the mA3 and gGag proteins 
are transient.   Human APOBEC3G has been suggested to associate with lipid rafts in 
cells
116
.  An association of mA3 with lipid rafts has not been demonstrated, however 
 
62 
 
Figure 4.3. Localization of mA3 and gGag in an infected cell. 3T3/mA3 infected with the 
gGag
+
 MuLV. At 6, 12, 24, and 48 hours post infection cells were processed for 
colocalization analysis with monoclonal rat anti-HA and DylightFluor 488 conjugated Goat 
anti-rat IgG (green) or polyclonal rabbit anti-glycosylated gag IgG and DylightFluor 594 
conjugated Goat anti-rabbit IgG (red) with Hoechst 33342 (blue) A). 3T3/mA3 cells infected 
with the gGag
+
 MuLV, processed for colocalization analysis 6, 12, 24 and 48 hours post 
infection (40 X). B). 3T3/mA3 infected with the gGag
+
 MuLV, processed for colocalization 
analysis 48 post infection (100X). 
gGag has been reported to associate with lipid rafts during the process of virus budding 
from the cell 
96,123
 . It was of interest to determine where mA3 and gGag localize in an  
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infected cell and determine if there is colocalization of the two proteins at different times 
after infection. 3T3 or 3T3/mA3 cells were grown on cover slips and infected with 
gGag
+
, gGag
-
 MuLVs or mock-infected. At different times after infection samples were 
processed for localization analysis. In agreement with other reports, mA3 was localized 
predominantly in the cytoplasm whereas gGag occupied a perinuclear location suggesting 
processing in the endoplasmic reticulum (Figure 4.3B).  At no time after infection did 
gGag appear to be colocalized with mA3 in gGag
+
 MuLV-infected cells (Figure 4.3A). 
Taken together with the immunoprecipitation studies, these findings suggest that gGag 
and mA3 do not directly interact in an infected cell.   
4.4.4 Localization of gGag and mA3 in virions 
 In an earlier report, both mA3 and gGag were identified as virion components in 
gGag
+
 virions released from mA3-expressing cells
101
.  Differences in localization or 
association in the virion with gGag may have an influence on how virion-associated mA3 
exerts its activity in an infection. It is unknown where gGag exists in the virion and the 
location of mA3 in the virion is unclear, though one report suggested that some mA3 
exists in the viral core
162
. If gGag is a type II transmembrane protein as reported
65,147
, it 
might be expected to be located on the surface of the virion as a component of the 
envelope and thus be unavailable to interact with mA3.  To determine the localization of 
gGag and mA3 in the virion, 3T3/mA3 cells were infected with gGag
+
 viruses.  Purified 
virion samples were pelleted through a 10-30% sucrose step gradient in which the 10% 
sucrose layer contained the non-ionic detergent, IGEPAL. Non-ionic detergents such as 
IGEPAL or NP-40 have been used in similar gradients in several reports to separate viral 
cores from the membrane bound virion components
3,136,140,162
.Virion pellets were 
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Figure 4.4. Isolation of viral cores from 
virions produced in mA3 cells. gGag
+
 or 
gGag
-
 MuLVs from mA3/3T3 cells were 
purified and sedimented through a 10-30% 
sucrose step gradient in PBS with IGEPAL in 
the 10% layer of the sucrose gradient at a 
concentration of 5%. Resulting pellets were 
analyzed by immunoblot technique with 
monoclonal anti-HA HRP-conjugated 
antibody,  polyclonal rabbit anti-gGag HRP-
conjugated antibody, polyclonal goat anti-gp-
70 antibody or an HRP-conjugated 
monoclonal anti-capsid (p30) antibody (mAb 
18-7).   
analyzed via immunoblot techniques. Under conditions in which the virion membrane 
envelope protein gp70 (SU) is completely stripped from the virion, both mA3 and gGag 
proteins persist in the sedimented material suggesting that both proteins are components 
of the viral core.  Thus, their virion localization does not preclude an interaction between 
them (Figure 4.4).  It is noteworthy that conditions that result in the loss of the SU protein 
from virions also results in the loss of substantial levels of the major virion core protein, 
p30 (CA) and may reflect a similar loss of mA3 and gGag from the virion core during 
their fractionation
162
.   
 
 
 
 
 
  
 
 
 
 
 
4.4.5 Interactions between gGag and mA3 in virions   
 In our earlier studies, we observed that virions that have incorporated mA3 
exhibit a lower infectivity and that this inhibition is gGag-dependent
101
. The finding that 
both mA3 and gGag exist in the virion core suggests the possibility of an interaction 
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between mA3 and gGag in the virion that was not observed in the cell.  Virions were 
collected from mA3 cells infected with gGag
+
 or gGag
-
 MuLVs 48 hours post infection. 
The virions were lysed and immunoprecipitated with anti-HA or anti-gGag conjugated to 
protein G magnetic beads. The immunoprecipitated samples were analyzed by 
immunoblotting procedures.  An antibody to mA3 was able to precipitate mA3 but did 
not result in the coprecipitation of gGag (Figure 4.5).  There are a number of possible 
explanations for the inability to demonstrate an interaction between mA3 and gGag using 
the mA3 antibody.  These include stoichiometric differences, stearic hindrance, or 
differences in antibody affinities.  In contrast, the reciprocal experiments clearly 
demonstrated that the mA3 protein was precipitated by antibodies to gGag in virions 
containing gGag but not from gGag
-
 virions indicating an interaction between mA3 and 
gGag in the virion (Figure 4.5).   
 
 
 
 
 
 
 
 
  
 
 
Figure 4.5. Immunoprecipitation of mA3 
containing virions. gGag
+
 or gGag
-
 MuLVs 
from mA3/3T3 cells were purified and 
immunoprecipitated with Protein G beads 
conjugated with monoclonal anti-HA antibody 
or the polyclonal rabbit anti-glycosylated gag 
antibody  Resulting complexes were analyzed 
by immunoblot technique with monoclonal 
anti-HA HRP-conjugated antibody or the  
polyclonal rabbit anti-gGag HRP-conjugated 
antibody. 
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4.4.6 The cellular mA3 protein does not induce G-to-A hypermutation in viral 
transcripts  
 mA3 has been reported to induce hypermutation in the reverse transcripts of 
several retroviruses including the XMRV and AKV MuLVs as well as HIV resulting in a 
reduction of infectivity
14,74,110
. Our previous report revealed that both cellular and virion-
associated mA3 inhibited the gGag
-
 MuLV but not the gGag
+
 MuLV
101
. It is possible that 
this inhibition was the result of deamination mediated by mA3.  To investigate this 
possibility, viral transcripts from 3T3/mA3 cells infected with gGag
+ 
or gGag
-
 viruses 
were amplified by PCR, cloned and sequenced to determine point mutations incurred 
during infection. Parallel experiments were performed in 3T3 cells devoid of mA3.   
DNA was isolated early (24 hours) after infection to limit the analyses to transcripts that 
had undergone a single replication cycle. No evidence of G-to-A hypermutation was 
observed, nor was there a significant difference in the G-to-A mutation rate between 
transcripts generated in gGag
+
 or gGag
- 
MuLV-infected cells.  Surprisingly, a 
significantly higher overall point mutation rate was observed in transcripts from 
3T3/mA3 cells infected with the gGag
-
 virus compared to 3T3/mA3 cells infected with 
the gGag
+
 MuLV while a significant difference in overall mutation rate was not observed 
in 3T3 cells (Figure 4.6).  Examination of the mutation rates for all possible base changes 
did not suggest the prevalence of a particular type of mutation contributing to the overall 
mutation rate difference (data not shown).   These results suggest that mA3 may exert an 
influence on reverse transcription independent of cytidine deaminase activity. 
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Figure 4.6. The mutation rates of samples exposed to cellular mA3. For analysis of 
cellular mA3s activity, 3T3 or 3T3/mA3 cells were infected either gGag
+
 or gGag
-
. 
Twenty-four hours after infection cells were lysed and viral sequences amplified by 
PCR, cloned and sequenced. The mutation rates for each clone were averaged to give the 
mean mutation rate as well as the standard error. gGag
+
 NIH3T3/mA3=81 clones, gGag
-
 
NIH3T3/mA3=42 clones, gGag
+
 NIH3T3=63 clones, gGag
-
 NIH3T3=78 clones. 
 
 
 
 
 
 
 
4.4.7 Mutation rates in transcripts generated by cell-free virions 
 Uracil-containing DNA is rapidly degraded in cells by apurinic/apyrimidinic 
endonuclease (APE)
13,105,185
.  The cytidine deaminase activity of mA3 results in a 
conversion of cytidine to uracil in the single-stranded transcripts generated by RT and it 
is possible that such transcripts are rapidly eliminated.  If this were to occur it would bias 
the analyses of the mutation rate in infected cells and hypermutation would be apparent in 
a reaction without cellular factors.  To determine if cellular factors mask the true 
deamination rate, cell-free virions produced from mA3 cells infected with gGag
+
 or 
gGag
-
 MuLVs were isolated and employed in endogenous RT reactions to generate 
transcripts in the absence of cellular factors.   The determination of the G-to-A and 
overall mutation rates in the endogenous reverse transcription reactions did not reveal 
evidence of hypermutation nor were significant differences in mutation rates observed 
between the samples (Figure 4.7). Taken together, these mutational analyses suggest that 
cytidine deamination is not the main mechanism used by mA3 to inhibit MuLVs in a 
gGag-dependent manner. 
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Figure 4.7. The mutation rates of samples in the endogenous viral reactions. For 
analysis of mA3s activity in a cell free environment, 3T3 or 3T3/mA3 cells were 
infected either gGag
+
 or gGag
-
. Virions were collected and used in cell-free 
endogenous RT reactions. Viral sequences amplified by PCR, cloned and sequenced. 
The mutation rates for each clone were averaged to give the mean mutation rate as well 
as the standard error. gGag
+
 purified from NIH3T3/mA3=152 clones, gGag
-
 purified 
from NIH3T3/mA3=169 clones, gGag
+
 purified from NIH3T3=164 clones, gGag
-
 
purified from NIH3T3=156 clones. 
 
 
 
 
 
 
 
 
4.4.8 Mutation rates in transcripts induced by virion-associated mA3 in infected 
cells 
 It has been reported that cellular hA3g reduces the level of accumulated reverse 
transcripts in infected cells but does not induce G-to-A hypermutation
29
.  In contrast, 
virion-associated hA3g induces G-to-A hypermutation upon infection
26,27
.  To determine 
if virion-associated mA3 exerted a similar affect, naïve Mus dunni cells were infected 
with viruses released from 3T3 or 3T3/mA3 cells.  Twenty-four hours post infection viral 
transcripts were analyzed for point mutations as described above.  No evidence of 
hypermutation was apparent nor were significant differences observed in the G-to-A 
mutation rate or in the overall mutation rates between the samples (Figure 4.8).  It is 
noted that the experiments determining the mutation rates of virion-associated mA3 are 
complicated by the procedures employed to generate the viruses.  Progeny viruses were 
obtained after infection of 3T3 cells or 3T3/mA3 and incurred point mutations during this 
process.  Although precise determinations of mutation rate are compromised by this 
process, hypermutation as a result of virion-associated mA3 would be apparent.   
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Figure 4.8. The mutation rates of samples exposed to virion-associated mA3. For 
analysis of virion-associated mA3s activity, 3T3 or 3T3/mA3 cells were infected either 
gGag
+
 or gGag
-
. Virions were collected and used infect Mus Dunni cells. Cells were 
lysed and viral sequences amplified by PCR, cloned and sequenced. The mutation rates 
for each clone were averaged to give the mean mutation rate as well as the standard 
error. gGag
+
 from NIH3T3/mA3=87 clones, . gGag
-
 from NIH3T3/mA3=67 clones, 
gGag
+
 from NIH3T3=84 clones, . gGag
-
 from NIH3T3=21 clones 
 
 
 
 
 
 
 
 
 
 
4.4.9 Cellular mA3 reduces viral transcript accumulation in a gGag-dependent 
manner 
 APOBEC3 proteins have been reported to utilize hypermutation-independent 
mechanisms to inhibit retroviral replication 
4,29,79,100
. In this regard, a partial inhibition of 
M-MuLV by mA3 was reportedly associated with a reduction in the total amount of viral 
DNA accumulated in the cell
18
.  In our experiments cellular mA3 was shown to inhibit 
viral replication in a gGag-dependent fashion
101
.  It is possible that mA3 exerts an 
inhibitory effect on reverse transcription resulting in reduced levels of viral transcripts in 
infected cells. To determine if gGag influences the accumulation of viral DNA in infected 
cells, 3T3 or 3T3/mA3 cells were infected by gGag
+
 or gGag
-
 MuLVs and the level of 
accumulated transcripts determined.  At 24 hours after infection, PCR amplification of 
viral DNA revealed a striking reduction in the transcript levels in 3T3/mA3 cells infected 
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Figure 4.9. Quantification of viral transcripts in infected cells expressing mA3. 
gGag
+
 and gGag
-
 viruses were used to infect 3T3 and mA3 cells. Eight (B) and twenty-
four (A) hours after infection cells were lysed and viral sequences amplified by PCR. 
GAPDH PCR products were used as loading controls and samples were quantitated using 
a standard curve.  
with the gGag
-
 virus compared to levels found in 3T3 cells (Figure 4.9B).  In contrast, no 
significant reduction in transcript levels between the two cell lines was observed after 
infection by the gGag
+
 virus.    These results suggest a function of cellular mA3 that is 
inhibited by the presence of gGag that correlates with the reduction of infectivity.   
 
 
 
 
 
 
 
 
 At 24 hours after infection it is expected that most viral DNA in the cell exists as 
integrated proviruses in the host genome.  Thus, the reduction in viral DNA at this time 
could reflect processes that occurred after reverse transcription rather than an effect of 
mA3 on reverse transcription itself.  To examine this possibility, viral transcript levels 
were determined 8 hours after infection.  At this time, very little, if any, viral DNA would 
be in the form of integrated proviruses and would more closely reflect immediate 
products of reverse transcription.  These analyses also revealed a significant decrease in 
the level of transcripts in 3T3/mA3 cells compared to 3T3 cells when infected with the 
gGag
-
 MuLV (Figure 4.9A).  A similar difference in the level of transcripts in these cells 
was not observed upon infection with the gGag
+
 virus.   These results suggest that the 
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reduction in viral transcripts in cells infected by the gGag
-
 virus in the presence of 
cellular mA3 is the result of an effect of mA3 on reverse transcription rather than a 
subsequent process during infection.  
4.4.10 Viral transcript levels in cells infected by viruses containing mA3   
Our previous studies indicated that virion-incorporated mA3 is also inhibitory to 
infection in a gGag-dependent manner
101
.  In these studies a substantial reduction in the 
infectivity of individual virions (specific infectivity) was observed.  The experiments 
above suggest that the reduction in transcripts of gGag
-
 viruses in the presence of cellular 
mA3 occurs at the level of reverse transcription rather than at a later stage of infection.  If 
the inhibition of specific infectivity is due to inhibition of reverse transcription occurring 
at a post-entry stage of infection, then infection of naïve cells by an equal number of 
gGag
+
 or gGag
- 
MuLVs containing mA3 would be expected to result in a reduction of 
transcripts of the gGag
-
 compared to the gGag
+
 virus.  Alternatively, it is possible that the 
mechanism of inhibition by cellular mA3 differs from that of virion-associated mA3 and 
might involve post-transcriptional events.  These analyses were undertaken to determine 
if the decrease in specific infectivity of mA3-containing gGag
-
 virions observed in earlier 
experiments (Chapter 3) was a result of  events occurring early in infection, before or 
during reverse transcription or, alternatively, at a later stage of infection subsequent to 
reverse transcription.  To examine this possibility naïve Mus dunni cells were infected 
with gGag
+
 and gGag
-
 MuLVs harvested from 3T3 or 3T3/mA3 cells and normalized to 
equal levels of virions.  Amplification of viral DNA 24 hours after infection revealed that 
viral transcripts were virtually undetectable in cells infected with gGag
-
 MuLVs 
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Figure 4.10. Quantification of viral transcripts in cells infected by virions containing 
mA3. gGag
+
 and gGag
-
 viruses (amount normalized with p30 quantification) from 3T3 or 
mA3 cells were used to infect Mus Dunni cells. Cells were lysed after 24 hours and viral 
sequences amplified by PCR. GAPDH PCR products were used as loading controls and 
samples were quantitated using a standard curve.  
containing mA3 (Figure 4.10).  These results are consistent with a process of mA3 
inhibition of reverse transcription which is circumvented by gGag.   
 
 
 
 
 
 
 
 
 
 
4.5 Discussion 
 In this chapter we investigated the mechanisms of the MuLV gGag-dependent 
escape from mA3 antiviral activity. We found in our experiments that mA3 was not 
depleted from infected cells. This differs from the way HIV uses its Vif protein to 
facilitate the proteolytic degradation of hA3g in infected cells
34
. Further suggesting the 
absence of a direct interaction in an infected cell, neither coimmunoprecipitation nor 
colocalization between mA3 and gGag was observed. Thus, an indirect interaction 
between mA3 and gGag in an infected cell is hypothesized to be responsible for the 
gGag-dependent inhibition of replication seen in mA3 cells.  
 Our analysis of the localization of gGag in the virion revealed that gGag is 
localized within the core along with mA3. This was a surprising result as gGag is 
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described as a transmembrane protein in an infected cell and would be expected to be 
localized with the envelope
65,147
. Nonetheless, this colocalization in the virion between 
gGag and mA3 could facilitate the abrogation of mA3 inhibitory activity.   
Coprecipitation experiments revealed that gGag and mA3 do interact in mature virions. 
The importance of this localization and interaction of mA3 and gGag in the virion is 
unknown, but may further signify a protective role for gGag from mA3 activity.  Further 
experimentation will be necessary to delineate the importance of interactions of mA3 and 
gGag in the virion.    
 Previous studies of the action of APOBEC3 proteins on retroviral replication have 
predominantly examined the activity of virion-associated hA3G or 
mA3
17,20,22,23,34,77,96,100,124,126,128,132,179
.  Our approach enabled the analysis of the action of 
mA3 expressed in the cell, which perhaps more closely reflects a natural retroviral 
infection.  In our initial studies, cellular mA3 exerted a marked inhibition of virus 
infection in a gGag-dependent manner
101
.  This result was somewhat unexpected 
considering that the incorporation of gGag in virions is thought to be quite low
63
.  Here, 
the analyses of G-to-A mutation rates of viral transcripts in mA3-expressing cells were 
not significantly different between cells infected by the gGag
+ 
or gGag
-
 viruses.  
However, a significant increase in the overall mutation rate was observed after infection 
by the gGag
-
 MuLV.  Further, the level of viral transcripts in mA3-expressing cells was 
strikingly reduced when infected with the gGag
-
 virus.  These results are consistent with 
our results of the effect of cellular mA3 on infectivity.    
 Our studies have revealed that that virion-associated mA3 reduced the specific 
infectivity of virions in a gGag-dependent manner
63
 which was reflected in levels of viral 
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transcripts in infected cells. This observation is not without precedent, as another report 
indicated that mA3 may also possess deaminase-independent  activity
18
. While a high 
number of G-to-A mutations was not seen in M-MuLV, the transcript levels were reduced 
in an amount comparable to the reduction in infectivity
18
. This suggests that the gGag of 
M-MuLV may not completely block the action of mA3.  It is noted that analyses of other 
MuLV sequences reveal extensive differences in their gGags including deletions and 
amino acid substitutions (data not shown).   In this regard, XMRV exhibits termination 
codons in the sequence encoding gGag and has been reported to be susceptible to the 
action of mA3. 
 Inhibition of MuLVs by cellular or virion-associated mA3 occurs in a gGag-
dependent manner. The precise mechanism by which virion gGag abrogates the action of 
mA3 is unclear.  Considering the high infectivity to particle ratios reported for many 
retroviruses
165
, it is possible that a large number of “non-infectious” virions may 
nonetheless enter the cell and provide a sufficient amount of gGag protein to effect 
inhibition of cellular mA3.  Alternatively gGag present in the virion could protect the 
virus from inactivation by mA3.  Such an effect could be operative to protect against both 
cellular and virion-associated mA3.   Our results strongly suggest that the mechanism of 
inhibition by mA3 involves an effect on reverse transcription of the viral genome and is 
largely independent of G-to-A mutation. It is possible that gGag exerts a stabilizing effect 
during reverse transcription or perhaps in the integrity of other virion components.  It is 
also possible that gGag acts in a stearic manner preventing an interaction of mA3 with 
the RT or viral RNA.  In the absence of gGag, there is an increase in the overall point 
mutation rate and a reduction of the level of transcripts in infected cells in the presence of 
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mA3. These two effects may be linked, thereby causing both a decrease in transcription 
efficiency as well as a decrease in RT fidelity.  Further studies will help elucidate the 
protective effect of gGag against mA3 activity.  
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CHAPTER 5: Summary 
5.1 Discussion 
HIV evades the action of hA3G through expression of an accessory protein, Vif, 
however the means by which exogenous MuLVs evade the action of mA3 was 
unclear
28,162
. We have shown that gGag acts as an antagonist of cellular and virion-
associated mA3 in vitro and have found gGag to be essential for in vivo replication in 
mA3 expressing mice. The mechanistic basis for these observations is largely 
independent of G-to-A mutation but is associated with a reduction of reverse transcripts 
in infected cells. 
 Inhibition of infectivity by mA3 was observed in two distinct contexts in our in 
vitro system: during the initial infection in which viruses devoid of mA3 infect cells 
expressing mA3 (cellular mA3); and during the subsequent infection in which viruses 
containing mA3 (virion-associated mA3) infect naïve cells not expressing mA3.  
Inhibition by cellular mA3 is not without precedent. It has been reported that M-MuLV
123
 
and mouse mammary tumor virus
138
 are partially inhibited by cellular mA3. HIV has also 
been reported to be inhibited by cytoplasmic hA3g
196
.  Nevertheless, it was unexpected 
that cellular mA3 exerted a gGag-dependent effect on MuLV infectivity in the absence of 
virion-associated mA3 considering that the level of gGag incorporated into the virion is 
low compared to that which is expressed in an infected cell
54,63
.  Furthermore, the small 
amount of gGag in the virion would be expected to associate with the viral envelope as a 
type 2 transmembrane protein
65,147
.  Our experiments involving the localization of gGag 
in the virion shows clearly that it is associated with the virion core. There are many 
possible functional consequences of this localization. One of these is that gGag may serve 
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to stabilize the structure of the virion. It has been reported that gGag is involved in virion 
release and that gGag
-
 M-MuLV exhibits an abnormal morphology during virion 
budding
121
.  Mature virions also differed from the wild-type virions by envelope lipid 
content but did not exhibit detectable morphological differences. In agreement with a 
number of other studies with different MuLVs, the gGag-deficient M-MuLV was not 
replication-defective in vitro but replication was severely limited in vivo
121
.  
 A number of mechanisms by which cellular mA3 might interact with gGag were 
examined in these studies.  The HIV-1 Vif protein mediates the degradation of hA3G in 
infected cells and it was possible that the presence of gGag might lead to mA3 
degradation
28,162
.   However, no significant difference in the level of mA3 expression was 
detected in the presence or absence of gGag. Thus, viral gGag does not lead to the 
proteolytic degradation of mA3 in vitro. The inhibition of cellular mA3 by gGag may 
involve a direct interaction of the proteins that delays or prevents mA3 from exerting its 
effect.  In this regard, immunoprecipitation experiments using antibodies directed at 
either protein did not result in coprecipitation of the proteins. It is possible that 
interactions between cellular mA3 and gGag may exist but be too weak or fleeting to be 
detected by immunoprecipitation techniques.  If the proteins do interact in infected cells, 
it is possible that colocalization to the same cellular compartment might be detected by 
confocal microscopy; however, no specific colocalization of the two proteins was 
detected when examined at various times after infection.  In the absence of evidence 
supporting a direct interaction, it was surmised that there may be an indirect interaction 
between cellular mA3 and viral gGag that enables the virus to escape the activity of mA3.
 Although the mutation data did not reveal a substantial cytidine deaminase 
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activity for cellular mA3, a higher overall mutation rate was observed with gGag
-
 than 
with gGag
+
 MuLVs.  This may reflect a functional role of gGag in promoting the fidelity 
or stability of reverse transcription and counteracting a destabilizing action of mA3.    
Such a role is consistent with the location of gGag in the virion and suggests it may 
interact with RT, RNA or other virion components in the reverse transcription complex to 
stabilize the reverse transcription reaction. It has been reported that APOBEC3 proteins 
exert deaminase-independent inhibitory activity on retroviral replication, though the 
mechanism by which it is accomplished is poorly defined.  In this regard a recent study 
reported that M-MuLV was partially inhibited by mA3
18
.  An elevated G-to-A mutation 
rate was not observed, however, the transcript levels were reduced in an amount 
comparable to the reduction in infectivity.  Similarly, we observed a striking inhibition of 
viral transcription levels after infection of cells with the gGag
-
 virus.  While the gGag
+
 
transcript levels remained consistent between 3T3/mA3 and 3T3 cells, the gGag
-
 
transcript levels were significantly reduced in the presence of mA3. A number of studies 
have reported varying susceptibilities of MuLVs to mA3
110,123,162,188
 .   Differences in the 
susceptibility of MuLVs to inhibition by cellular mA3 could reflect differences in the 
efficacy of their respective gGags to counteract mA3. In this regard, a comparison of the 
gGags of different MuLVs reveals subtle to extensive differences which include deletions 
as well as amino acid substitutions (data not shown).   
 We observed that progeny virions released from mA3 expressing cells were also 
inhibited in a gGag-dependent manner when tested on cells not expressing mA3.  It is 
possible that both gGag
+
 and gGag
-
 MuLVs incorporate mA3 into virions at similar levels 
but that the incorporation of mA3 is qualitatively different between the MuLVs.   The 
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location or association of mA3 with virion components may be altered in response to the 
presence of gGag.   The observation that mA3 is located in the virion core for both the 
gGag
+
 and gGag
-
 MuLVs argues against this possibility. The presence of both gGag and 
mA3 in the virion core may allow for an interaction between the two proteins.   In 
contrast to the immunoprecipitation analyses in infected cells, coprecipitation of mA3 
and gGag was observed in the virion.  The proximity of mA3 and gGag to each other in 
the virion or the presence of a binding intermediate, such as the RNA genome or other 
binding partners may facilitate coprecipitation in the virion but not in the cell. Further 
experimentation will reveal if viral RNA or other proteins are associated with mA3 and 
gGag.  
The binding interaction observed in these analyses may function to prevent mA3 
from exerting its antiretroviral activity on the virus during reverse transcription upon 
infection. No statistically significant differences of the mutation rates were observed 
between any of the viruses regardless of virion incorporation of mA3 or gGag.  However, 
the transcript level was severely reduced in Mus dunni cells infected with the gGag
-
 
viruses produced from 3T3/mA3 cells. In these experiments the level of virus used to 
infect the Mus dunni cells was adjusted to the number of virions rather than the 
infectivity.  Assuming that the presence of mA3 in the absence of gGag does not alter the 
initial events of viral receptor binding and fusion to enter the cells, it is likely that the 
process of reverse transcription was altered in the infected cells.  Conversely, in cells 
infected with the wild-type virus possessing gGag and mA3, inhibition was presumably 
prevented by the interaction of gGag and mA3.   
 The results of the in vitro studies were corroborated in our in vivo investigations.  
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There was a striking inhibition of replication in vivo of the gGag
-
 MuLV compared to the 
gGag
+
 MuLV in mice expressing mA3.  In mice lacking mA3, the level of Gag
-
 
replication was restored to the high levels of gGag
+
 MuLV.  These results were obtained 
in both the 129/Ola and C57BL/6 genetic background.  Development of reagents, such as 
a specific mA3 antibody, will facilitate in vivo studies as one could determine beyond 
mRNA levels the amount and type of mA3 expressed in tissues and the amount that is 
incorporated into virions. The development of specific tags and/or refinements in the 
purification of virions from mice may also make it possible to more precisely determine 
the amount of gGag incorporated into virions.  
5.2 Future directions 
 Based on the localization of gGag in the virion core, gGag may serve a function in 
stabilizing the mature virion or the reverse transcriptase complex. To this end, a recent 
report indicated that gGag exhibits some functional similarities to the Nef protein of 
HIV
149
.  Nef is an accessory protein of HIV that exhibits many different functions 
including increasing the efficiency of reverse transcription
168
.  Nef is incorporated into 
virions and facilitates replication both in vitro and in vivo
19,94,95,144
. Nef-deficient viruses 
exhibit reduced infectivity which can be restored by complementation with gGag.  
Indeed, the complementing activity of gGag was discovered in cells which had been 
inadvertently infected with an MuLV
149
.  It is unknown if Nef has an influence on the 
action of APOBEC3 proteins nor is it clear if Nef can complement the effect of gGag on 
MuLV replication  Further studies of the action of Nef may provide insight into the 
precise mode of action of gGag on the activity of mA3. 
 The susceptibility of the gGag
-
 MuLV to cellular mA3 may occur by an indirect 
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mechanism.  In this regard, it has been reported that gGag is involved in virion release 
and that gGag
-
 M-MuLV exhibits an abnormal morphology during virion budding
121
.  It is 
conceivable that mature virions may be altered from an mA3-resistant to an mA3-
susceptible phenotype.  If an altered mA3-sensitive phenotype exist, then it may be 
possible to restore it by infecting cells that contain a gGag construct or by superinfecting 
cells with another MuLV encoding a functional gGag. Indeed, Low et al
121
 showed that 
expressing a gGag construct in a retroviral packaging cell line restored the gGag
-
 budding 
virion phenotype to a more common spherical one. It is of interest to determine if the 
expression of gGag in a cell would restore the infectivity of progeny virions on mA3 
expressing cells.  Further, if complementation in trans could be demonstrated, it might be 
possible to compare the efficacies of different MuLV gGag proteins.     
 In the in vitro studies, the gGag
+
 MuLV was not inhibited, however, there has 
been a number of studies that  report partial to marked inhibition of other gGag
+
  
MuLVs
109,122,162,187
.  One report compared the inhibitory effects of mA3 on M-MuLV and 
AKV MuLV. AKV was inhibited to a greater extent than M-MuLV
108
.  Inhibition of AKV 
by mA3 exhibited G-to-A mutations whereas M-MuLV did not
107,162
. The susceptibility 
of MuLVs to inhibition by mA3 could represent a difference in the efficacy of gGags to 
counteract mA3.  Comparing the gGag sequences of multiple MuLVs revealed 
differences in their amino-terminal fragments. It is of interest to determine if the 
inhibition of mA3 by gGag of viruses utilized in this study can be generalized to other 
gGag
-
 viruses.  This could provide insight into differences in the activities of gGag 
proteins from different sources.  As mentioned above, it may also be possible to directly 
compare efficacies of different MuLVs through complementation studies.   
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 Some studies have noted that there are allelic differences between different mouse 
strains in the both the levels and isoforms of expressed mA3.  Some mice express the full 
length protein, while others express a Δ exon 5 or a Δ exon 2 splice variant
111,139,162,163
.  
There are conflicting reports on the inhibitory activities of these variants. In our studies, 
there was a gGag-dependent inhibition in 129/Ola mice, which predominately produce 
the full-length version, and in C57BL/6 mice, which predominately produce the Δ exon 5 
splice variant. It is unknown if there are differences in the activities in vivo as the 
expression levels are different between mouse strains. In order to address this issue, it 
will be necessary to conduct parallel in vitro studies using cells expressing full length 
mA3 as well as the spice variant forms of the protein. 
During the course of these investigations it was noted that some uninfected mA3
-/-
 
mice developed a proliferative disease at 6 to 8 months of age.  Spontaneous proliferative 
diseases in mice are often accompanied by the expression of endogenous retroviruses.  It 
will be of interest to determine if the expression of endogenous viruses is demonstrable in 
mA3
-/-
 mice that have developed proliferative disease.   
In closing,  the studies conducted for this dissertation are of particularly interest in 
light of recent reports indicating cross-species retroviral infections from mouse to 
humans
120,166,193
.  In some studies, these infections are evidenced by the detection of 
endogenous gGag-deficient MuLVs.  Infection of mice by gGag
+
 viruses may inhibit the 
activity of mA3 and facilitate the mobilization of endogenous MuLVs through 
pseudotyping.  Certain MuLVs such as amphotropic and xenotropic MuLVs encode intact 
gGag proteins and can infect humans.  Pseudotyping of endogenous MuLVs by these 
viruses could account for the transmission of endogenous gGag-deficient MuLVs.  
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